Article:Modified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic Toxins (5198570)

From ScienceSource
Jump to: navigation, search

This page is the ScienceSource HTML version of the scholarly article described at Its title is Modified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic Toxins and the publication date was 2016-12-16. The initial author is Nans Florens.

Fuller metadata can be found in the Wikidata link, which lists all authors, and may have detailed items for some or all of them. There is further information on the article in the footer below. This page is a reference version, and is protected against editing.

Converted JATS paper:

Journal Information

Title: Toxins

Modified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic Toxins

  • Nans Florens
  • Catherine Calzada
  • Egor Lyasko
  • Laurent Juillard
  • Christophe O. Soulage
  • Raymond Vanholder (Academic Editor)

1CarMeN, INSERM U1060, INRA U1397, INSA de Lyon, Université Claude Bernard Lyon 1, University of Lyon, F-69621 Villeurbanne, France; (C.C.); (E.L.); (L.J.); (C.O.S.)

2Hospices Civils de Lyon, Department of Nephrology, Hôpital E. Herriot, F-69003 Lyon, France

Publication date (epub): 12/2016

Publication date (collection): 12/2016


Chronic kidney disease (CKD) is associated with an enhanced oxidative stress and deep modifications in lipid and lipoprotein metabolism. First, many oxidized lipids accumulate in CKD and were shown to exert toxic effects on cells and tissues. These lipids are known to interfere with many cell functions and to be pro-apoptotic and pro-inflammatory, especially in the cardiovascular system. Some, like F2-isoprostanes, are directly correlated with CKD progression. Their accumulation, added to their noxious effects, rendered their nomination as uremic toxins credible. Similarly, lipoproteins are deeply altered by CKD modifications, either in their metabolism or composition. These impairments lead to impaired effects of HDL on their normal effectors and may strongly participate in accelerated atherosclerosis and failure of statins in end-stage renal disease patients. This review describes the impact of oxidized lipids and other modifications in the natural history of CKD and its complications. Moreover, this review focuses on the modifications of lipoproteins and their impact on the emergence of cardiovascular diseases in CKD as well as the appropriateness of considering them as actual mediators of uremic toxicity.


1. Introduction

Chronic kidney disease (CKD) is associated with an increased risk of cardiovascular disease as these patients develop accelerated atherosclerosis [[1],[2],[3],[4],[5],[6],[7]]. The main mechanisms underlying this increased CV risk in this population are oxidative stress [[8]], accumulation of uremic toxins [[9]], dyslipidemia and phosphocalcic metabolism disorders. Enhanced oxidative stress and uremic environment can strongly modify circulating lipids and lipoproteins leading to profound alterations of their biological properties. Indeed, lipid peroxidation by-products such as malondialdehyde (MDA) are increased and are negatively correlated with the glomerular filtration rate in CKD. Large amounts of oxidized lipids, such as F2α-isoprostanes are associated with CKD progression [[10]].

Renal dysfunction is also associated with many perturbations in lipoprotein metabolism leading to dyslipidemia and accumulation of atherogenic particles [[11]]. Lipoprotein metabolism is complex and is associated with multisite regulations (involving liver, colon, plasma, macrophages and endothelial cells) that can be individually affected by CKD. Post-translational modifications such as carbamylation, glycation or oxidation particularly affect circulating lipoproteins (both on their protidic or lipidic fraction) leading to altered behaviors in the cardiovascular system. These particular modifications of lipid metabolism in CKD are a novel way of explaining the failure of statins in the prevention of cardiovascular diseases in hemodialysis patients [[12],[13]].

According to the European Uremic Toxin Work Group (EuTox,, uremic toxins are defined as accumulated solutes, normally excreted by the kidneys, that interact negatively with biological functions [[9]]. Even if some lipids and lipoproteins are neither excreted by the kidneys in normal conditions nor accumulated in CKD, their modifications and altered metabolism unambiguously change their interactions with biological functions and especially cardiovascular physiology. This review will explain why in CKD, some lipids and lipoproteins can be considered as uremic toxins.

2. Uremic Lipoproteins, Evidences of Toxicity

2.1. Dyslipidemia in CKD, A Unique Phenotype

CKD is associated with dyslipidemia associating hypertriglyceridemia, elevated LDL cholesterol, an accumulation of ApoB containing lipoproteins, increased concentrations of lipoprotein(a) particles and low HDL levels [[14],[15]]. Many recent reviews analyzed this dyslipidemia in detail [[11],[14],[16],[17],[18]]. Dyslipidemia in CKD is unique for many reasons. First, cardiovascular (CV) diseases are the leading cause of mortality in CKD patients. Number of cardiovascular events has been strongly correlated with GFR decline [[1]] and despite constant improvement of renal suppletion therapies, such as hemodialysis, this cardiovascular mortality remains at the forefront [[19]]. Traditional strategies for cardiovascular prevention, including the prescription of statins, failed in some CKD populations. Even if post hoc analysis of large prospective studies sketched a potential benefit in early stages of CKD [[20],[21],[22]], this positive effect is diminished in advanced stages (4 and 5), either on intima/media thickness [[23]] or cardiovascular mortality and related events, as shown by 4D [[12]] and AURORA [[13]] studies. Recent meta-analysis from the Cochrane Collaboration confirmed this observation in dialysis patients [[24]] but also suggested its interest for CKD patients who did not require hemodialysis [[25]] or transplant recipients [[26]]. However, beyond its effects on CV mortality, statins exhibited beneficial effects for impeding renal failure progression [[27],[28]]. Indeed, statins can modulate intracellular pathways of inflammatory and fibrogenic responses and inhibit the proliferation of mesangial and renal tubular epithelial cells [[27],[29]]. Moreover, recent data corroborate their importance in lipid control to prevent the progression of CKD. The increase of one standard deviation of TG level and TG/HDL-cholesterol ratio was correlated with an increased risk of developing CKD. Additionally, increases of HDL-cholesterol level, LDL-cholesterol/ApoB and HDL-cholesterol/ApoAI ratios seemed to be protective [[30]].

2.2. Very Low Density, Intermediate Density Lipoproteins (VLDL, IDL) and Chylomicrons

An earlier report suggested that triglyceride-rich lipoproteins (TGRL), including chylomicrons, VLDL and their remnants, accumulate in CKD [[31]]. Okubo et al. found that ApoB48 levels, composed of chylomicrons and their remnants, are inversely correlated with GFR levels and increased proteinuria [[32]]. ApoB48 levels were also found elevated in ESRD diabetic patients [[33]]. In transplantation, ApoB gene polymorphism was associated with poor cardiovascular outcomes in patients presenting deletion of a part of ApoB signal peptide [[34]].

TGRL, chylomicrons and VLDL, deliver lipids to peripheral cells. After delivering their triglycerides cargos, these lipoproteins are converted into IDL and LDL or are removed by the liver. Chylomicrons and nascent VLDL need apolipoprotein C and E (ApoC, E) for their maturation. These proteins are delivered by HDL-2. In CKD, HDL metabolism is impaired and HDL-3 are not maturated into HDL-2 due to a lecithin-cholesterol acyl-transferase (LCAT) deficiency [[35],[36],[37]]. ApoE and ApoC are necessary for binding and activation of lipoprotein lipase (LPL) respectively and such defect leads to a reduced release of triglycerides in peripheral tissues and leads to an accumulation of TGRL. Moreover, significant evidence showed that peripheral LPL is lacking in CKD [[38],[39],[40]].

In normal conditions, VLDL and chylomicrons are transformed into IDL and chylomicrons remnants after lipolysis in peripheral tissue. Then, part of IDL and remnants are removed by the liver via LDL receptor protein (LRP) that has been found to be downregulated in CKD [[41]]. The other part of IDL is transformed into LDL by the removal of their triglycerides by the hepatic lipase and enrichment in cholesteryl esters from HDL-2 by cholesteryl-ester transfer protein (CETP). As previously described, lack of HDL-2 impedes this phenomenon and leads to the accumulation of highly pro-atherogenic IDLs [[42]]. Moreover, there is a downregulation of hepatic lipase expression in CKD [[43],[44],[45]]. A part of VLDL is removed by their binding on VLDL-receptor in myocytes and adipocytes. The expression of this receptor is also down-regulated in CKD [[46],[47]] (Figure 1).

2.3. Low Density Lipoproteins (LDL)

As LDL remains the main target of cardiovascular prevention strategies, their metabolism in CKD was the focus of numerous works. Patients in early stages of CKD commonly exhibit elevated LDL-cholesterol level [[48]]. Uncommonly, ESRD patients and particularly HD patients have normal or reduced LDL cholesterol and total cholesterol levels and interestingly, an inversed association has been found between cholesterol level and mortality in those patients [[49],[50],[51]]. Beyond LDL-cholesterol level itself, CKD leads to various structural modifications of lipids and proteins that make up LDL particles.

Oxidized-LDLs (oxLDL) result from the action of enzymatic and non-enzymatic pathways of oxidative stress. Several levels of oxidation from electronegative (minimally modified) to extensively oxidized LDL can coexist in the bloodstream and lead to the activation of several pathways involved in atherosclerosis through their binding to scavenger receptors [[52]]. In CKD, there is substantial evidence that those oxLDL accumulate, especially in HD patients [[53],[54],[55],[56]]. oxLDL concentration was shown to increase after an HD session [[56]]. Moreover, oxLDL are correlated with left ventricular hypertrophy in pediatric HD patients [[57]] and with the intensity of peripheral arterial disease [[58]]. Oxidized epitopes of LDL can activate immunity and then lead to the formation of antibodies directed against oxLDL. OxLDL/antibodies against oxLDL ratio was also correlated with carotid atherosclerosis and cardiovascular events in HD patients [[59]].

As stated above, CKD is associated with an enhanced MPO activity that plays a substantial role in the generation of post translational modification derived products (PTMDPs). Indeed, serum MPO levels have been correlated with mortality in an HD cohort [[60]] and with oxLDL levels [[61]]. MPO can promote LDL modifications through several mechanisms. First, reaction between HOCl generated by MPO and tyrosine residues of ApoB100 creates 3-chlorotyrosine, found in atherosclerotic lesions [[62]] and well-known for their pro-atherogenic properties through their binding with lectin-like oxidized LDL receptor 1 (LOX-1) [[52],[63]]. Interestingly, 3-chlorotyrosine levels were found to be higher in HD patients compared to healthy volunteers [[64]]. Secondly, MPO can also catalyze the generation of reactive nitrogen species (RNS) and create pro-atherogenic nitrosilated-LDL [[65]]. Thirdly, MPO catalyzed the addition of thiocyanate to the LDL (derived from the decomposition of urea) and leads to the formation of carbamylated-LDL (cLDL) [[66],[67]]. These cLDL have potent pro-atherogenic effects such as the transformation of macrophages into foam cells [[68]] through their binding to the pro-atherogenic CD36 receptor [[69]] (upregulated in CKD [[70]]) and associated with endothelial toxicity [[71],[72]] and platelet aggregation [[73]] through LOX-1 [[74]]. cLDL levels are raised by chronic uremia and were linked with atherosclerosis in CKD [[75],[76]].

2.4. High Density Lipoproteins (HDL)

Accelerated atherosclerosis in CKD patients and relative failure of statins in advanced stages of CKD demonstrate that traditional cardiovascular risk factors are not at the forefront. A recent focus on HDL quality rather than quantity revealed a potential role of HDL dysfunction in the set-up of cardiovascular disease in CKD.

HDL metabolism is impaired in CKD. In normal physiological conditions, ApoA1 and A2 are released into the circulation by the liver. These proteins are loaded with cholesterol and phospholipids to form nascent HDL. In CKD, ApoA1 and A2 levels are decreased [[77],[78]]. Then, nascent HDL binds to the ABCA-1 receptor on circulating macrophages and activates cholesterol ester hydrolase allowing their loading with cholesterol. AcetylCoA acyl transferase (ACAT) limits this reverse efflux of cholesterol from macrophages by catalyzing the esterification of intracellular cholesterol. In CKD, modifications of ApoA1 limit HDL binding on macrophages [[79]] and upregulation of hepatic ACAT-2 in CKD [[37],[80]] participates in the observed impaired cholesterol efflux. After its uptake, free cholesterol is esterified into cholesteryl esters by lecithin cholesterol acyl transferase (LCAT), which is transferred to the core of the lipoprotein. Nascent HDL are then transformed into discoid HDL-3 and then into spherical HDL-2 enriched in cholesterol. In CKD, LCAT level and activity are impaired [[35],[36],[37]], leading to the accumulation of HDL-3 and reduced level of HDL-2, especially in HD patients [[81]]. The latter, in normal conditions, enrich VLDL and chylomicrons with ApoC and E, essential for their normal metabolism (see above). Moreover, cholesterol ester transfer protein (CETP) transfers triglycerides in exchange for cholesterol from TGRL to HDL and LDL resulting in TG-enriched HDL-2 and LDL species. There is no evidence of deficit of CETP in CKD but as HDL-2 level is lowered, its activity may suffer. Then, HDL is cleared from their cholesterol content by their binding with hepatic SR-B1 receptor and the cycle starts again (Figure 1).

Beyond a dysfunctional metabolism, HDL is also a major target for oxidative stress and post-translational modifications. As stated above, CKD leads to a modification of ApoA1, impairing its binding on ABCA-1 [[79]]. As MPO activity is enhanced in CKD, MPO-modified ApoA1 results in decreased reverse cholesterol efflux and a reduced binding with ABCA-1 receptor [[82],[83]]. Moreover, MPO leads to the increased formation of 3-chlorotyrosine, an oxidation product of MPO, in HDL and impairs LCAT and paraoxonase activities and then anti-inflammatory proprieties of HDL [[84]]. MPO-modified HDL are also potentially involved in the generation of foam cells in atherosclerotic lesions through the activation of SR-B1 in macrophages [[85]] and increase of pro-inflammatory secretion activity and adhesion molecules expression in endothelial cells [[86]]. These MPO-modified HDL exhibit impaired anti-apoptotic properties in endothelial cells [[86]]. Interestingly, high levels of oxidized HDL are correlated to increased cardiovascular mortality in HD patients [[87]] as well as to HDL anti-inflammatory index elaborated by Kalantar-Zadeh et al. [[88]]. Recent analysis of HDL proteome showed an association of acute phase protein serum amyloid A with CKD-HDL that may participate in impaired biological functions [[89],[90]].

Normal HDL are known to be anti-atherogenic thanks to several properties [[17]]. First, HDL induces a reverse cholesterol transport from circulating macrophages. This property is well known to be atheroprotective [[91]]. In CKD, this function is dramatically impaired as CKD-HDL have reduced capacities of inducing this efflux [[81],[89],[92],[93],[94]]. Even in a pediatric CKD cohort, the deeper was CKD, the lower was the cholesterol efflux [[95]]. Moreover, restoration of renal function by transplantation is associated with an enhancement of these capacities without retrieving normal-HDL levels [[92]]. Nevertheless, Kopecky et al. sowed the seeds of doubt by showing that cholesterol efflux levels capacity in diabetic HD patients is not a prognostic marker of cardiovascular events [[96]].

Secondly, normal HDL increases the production of nitric oxide through the activation of eNOS in endothelial cells resulting in a vasorelaxant phenotype. In CKD, evidences show that HDL from CKD children lose their protective effect as the production of NO by endothelial cells is significantly reduced with HDL [[95]]. CKD-HDL can probably induce the uncoupling of eNOS from endothelial cells as the superoxide production in endothelial cells is significantly enhanced with CKD-HDL [[95]].

Thirdly, normal HDL inhibits the expression of adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1) and vascular adhesion molecule-1 (VCAM-1), which prevent the attachment of circulating monocytes to endothelial cells. In CKD, HDL promotes an enhanced expression of VCAM-1 and ICAM-1 on endothelial cells [[93],[95]]. Moreover, CKD-HDL upregulates the expression of pro-inflammatory mediators such as monocyte chemoattractant protein-1 (MCP-1), interleukin-1ß (IL-1ß) and tumor necrosis factor α (TNF-α) [[93],[94]].

Normal HDL exhibit anti-apoptotic effects on endothelial cells through the downregulation of caspase-3 activity [[97]]. CKD-HDL inhibits endothelial cell proliferation [[93]]. Finally, normal HDL has anti-oxidative properties thanks to PON1 and GPX enzymes on its surface. PON1 was firstly recognized as a hydrolytic enzyme for various toxic organophosphates. Mainly expressed in the liver and the kidney, this enzyme exhibited anti-oxidant properties against lipid peroxidation as it binds to HDL and in a minor part to VLDL [[98]]. Thus, this enzyme is considered as the main anti-oxidant enzyme bound to HDL. PON1 activity is lowered in CKD [[99],[100],[101]]. GPX is another important anti-oxidant enzyme at HDL surface. Its activity and expression on HDL are lowered in CKD [[35]].

2.5. Lipoprotein A (Lp(a))

Lp(a) is composed of a LDL-like particle bound with an apolipoprotein(a) (Apo(a)) on lysine residues of ApoB100. Apo(a) is secreted by the liver and contains a repetition of kringle-IV units. Genetic variants of Lp(a) and its concentration have been deeply correlated with coronary heart disease and cardiovascular morbidity [[102],[103],[104],[105]]. As its concentration is closely associated with OxPL/ApoB, Lp(a) may play a role in OxPL clearance even though its role(s) still remain unclear. Lp(a) levels were found to be risk predictors of all-cause mortality in HD patients [[106]]. Lp(a) accelerates atherosclerosis in a mouse model of CKD [[107]]. Moreover, Lp(a) clearance is partly done by the kidney explaining why its clearance is lowered in hemodialysis patients even if its generation does not seem to be higher than in healthy subjects [[108]]. However, in Tzanatos et al. study, Lp(a) levels seems to be increased after an HD session [[109]] while no change was found in Bossola et al. study [[56]]. As HD seems to be ineffective for Lp(a) clearance, it can explain higher levels in ESRD patients as its generation is not increased in these patients. Unlike hemodialysis, nephrotic syndrome exhibits enhanced secretion of Lp(a) by the liver [[110]]. In a nutshell, CKD exhibits higher levels of Lp(a) than in healthy subjects (Table 1) and it accumulates with CKD [[111]] severity while it decreases with renal transplantation [[112]], Lp(a) is a prototype candidate to be classified as a uremic toxin.

3. Oxidative Stress/Non-Oxidative Modifications of Lipids and Lipoproteins in CKD

3.1. Oxidative Stress, Lipid Peroxidation and Antioxidant Defenses

Oxidative stress is defined as a lopsided balance of the pro/anti-oxidant state in favor of the pro-oxidant [[129]]. The origin of this stress is the formation of reactive oxygen species (ROS) like superoxide anion O2•−, hydroxyl radical •OH or hydrogen peroxide H2O2. Major part of reactive oxygen species in our organism is produced by the mitochondrial respiratory chain [[130]], the NADPH oxidase [[131],[132]] and 5-lipooxygenase enzyme [[133]]. Other enzymes such as xanthine oxidase or NO synthase [[134]] can also provide ROS in pathological conditions. ROS, by many intertwined reactions, produce free radicals in the presence of transition metal ions (Fe2+, Cu2+) or carbon-composed molecules like proteins, nucleic acids or lipids. Nitric oxide (NO) can also yield free radicals often referred to as reactive nitrogen species (RNS). NO is generated by NO synthases and plays many roles in the regulation of vascular tone, permeability and platelet adhesion. NO can rapidly react with O2•− to generate a more oxidized form of a nitric product: the peroxinitric ion (ONOO−). The latter can easily react with proteins, lipids or nucleic acids, resulting in oxidized or nitrosylated forms.

As previously described, lipids can be affected by oxidative stress. First step of lipid peroxidation is the reaction of a free radical with a poly-unsaturated fatty acid (L). This reaction results in the formation of a lipid radical L•. This radical can react with oxygen and create lipid peroxyl radicals (LOO•). From this point, LOO• can react with other lipids and create new lipid radicals and lipid hydroperoxide (LOOH). The degradation of lipid hydroperoxide provides new lipid radicals (LO•, LOO•) and aldehydes as stable end-products of lipid peroxidation process (malondialdehyde or MDA, 4-OH-2,3-alkenals). F2α-isoprostanes are end-products from the oxidation of arachidonic acid (i.e., 20:4 (n-6)). These three end-products are routinely used for in vivo evaluation of lipid peroxidation level [[135],[136]]. However, there are other products of lipid peroxidation such as oxysterols and oxidized phospholipids that play a substantial role in the onset and progression of atherosclerosis and lipid dysmetabolism [[137]].

Under physiologic conditions, there is a basal rate of production of ROS as well as a limited production of oxidized molecules [[138]]. Nevertheless, this production of oxidants is balanced by a complex pattern of antioxidant mechanisms that protect the cells and tissues from oxidative damages. The protection from the ROS damage is permitted by antioxidant enzymes such as superoxide dismutase (SOD) which catalyses the dismutation of O2•− into H2O2, glutathione peroxidase (GPX) or catalase, which detoxifies H2O2 and other hydroperoxide containing molecules. Non-enzymatic antioxidants include reduced glutathione (GSH), which allows the scavenging of •OH and acts as a substrate for GPX as well as ascorbic and uric acids that are scavengers of •OH, singlet O2 and peroxyls radicals. Ferritin, ceruleoplasmin, transferrin, lactoferrin and metallothionein can also be regarded as antioxidant proteins as they trap transition metal ions and prevent ROS formation from Fenton reaction [[133]]. To prevent lipid peroxidation, aforementioned antioxidant molecules act together with several liposoluble antioxidants such as tocopherols, ubiquinol, flavonoids and carotenoids. Moreover, the protein paraoxonase-1 (PON1) from HDL is a major anti-oxidant preventing lipoproteins from oxidation although its exact mechanism remains unclear [[98]]. Some molecules such as tocopherols or curcumin, are considered as chain-breaking antioxidants, corresponding with their ability to intercept intermediary radicals during the lipid peroxidation process and then break the oxidative chain. Finally, albumin can be considered as a major antioxidant protein of the plasma. In fact, serum albumin can bind various ligands such as copper, iron, long chains fatty acids (LCFA), poly-unsaturated fatty acids (PUFAs) and cholesterol and prevent them from oxidative modifications [[139]]. It can also bind bilirubin [[140],[141]] and inhibit lipid peroxidation as well as prevent damages of α-tocopherol [[142]] and bind homocysteine. Albumin also contains a reduced cysteine residue (Cys34) which can scavenge hydroxyl radicals [[143]]. Due to the large amount of albumin in the plasma, it represents the largest amount of thiols available in the circulation [[144]]. Albumin also scavenges hypochlorous acid (HOCl) responsible for chlorination of proteins mediated by myeloperoxidase.

3.2. Oxidative Stress in CKD

Substantial literature is available about the enhanced oxidative stress in CKD [[145],[146],[147],[148],[149],[150],[151],[152],[153],[154]]. The unbalanced pro-oxidative state appears almost at the onset of CKD and increases as the glomerular filtration rate (GFR) declines [[8]]. There are multiple reasons for this enhanced oxidative stress and they are often intertwined.

As we will discuss later, antioxidant defenses are lowered in CKD leading to a higher sensitivity to oxidative stress induced by classical cardiovascular risk factors (hypertension, advanced age, diabetes and obesity [[155]]). Indeed, hypertension is well known to be a major state of oxidative stress [[156],[157]]. Upregulation of NADPH oxidase via the activation of renin-angiotensin system (RAS) is well-recognized as a major provider of ROS in hypertension [[157],[158],[159]]. In CKD, RAS has been directly linked with enhanced oxidative stress and CKD progression through the up-regulation of pro-oxidative pathways (NF-kB, NADPH oxidase, cyclooxygenase 2, 12-lipooxygenase) by angiotensin II and its binding to angiotensin-1 receptor [[159]].

Most antioxidant defenses are lowered in CKD. However, some controversies still exist as many studies produced conflicting results. Total antioxidant status is decreased in CKD [[160],[161]]. Nevertheless, the large range of techniques used for this determination and the numerous confounding factors in CKD make it difficult to interpret [[8],[162]]. The determination of Superoxide dismutase (SOD) activity is prototypical. Some studies found a decreased SOD activity in CKD patient [[163],[164]] while others reported a normal level of activity [[165]]. Surprisingly, SOD activity was even found to have increased in CKD [[166]]. As there are several isoforms of SOD (cytosolic, mitochondrial and extra-cellular), assays are difficult to extrapolate between all the different studies. As a matter of fact, SOD activity seems to be correlated with CKD stage and its activity is restored by several interventions in CKD patients (erythropoietin, vitamin E supplementation and kidney transplantation) [[167],[168]]. Similar contradictory observations were reported for catalase activity (e.g., either lowered [[169]], normal [[165],[170]] or increased [[160]]). Glutathione activity and concentration are lowered in CKD and are correlated with uremic toxins’ concentrations [[171],[172]] and glomerular filtration rate (GFR). PON1 activity is lowered in CKD [[98],[99],[100]]; however, further studies are needed to fully understand its implication on lipid dysmetabolism and lipoprotein dysfunction [[97],[173]] associated with CKD.

3.3. Post-Translational Modification Derived Products (PTMDPs) of Lipoprotein and Covalent Modifications of Lipids

Proteins and lipids are especially prone to oxidation and their irreversible oxidative modifications lead to a profound alteration of their biological functions. Carbonylation is the addition of compounds made from glycation and lipid peroxidation onto proteins. These residues can react with lysine and arginine residues and then create advanced glycation end products [[174]] (AGEs) and advanced lipoxidation end products [[175]] (ALEs). Proteins can also be carbonyled by direct oxidation by ROS [[176]]. 3-desoxyglucosone, D-arabinose, glyoxal can react with proteins and create AGEs as pentosidine and carboxy-methyl-lysine. Lipid peroxides of polyunsaturated fatty acids (PUFAs) such as 4-hydroxy-2-nonenal (4-HNE) and 4-hydroxy-2-hexenal (4-HHE) can also react with lysine, cysteine and histidine residues of proteins and create ALEs (Figure 2).

AGEs and ALEs have several biological effects involved in atherosclerosis [[177]]. AGEs have significant effects on lipids as they can make LDL more prone to oxidative modifications [[178]], increase glycated-LDL uptake from macrophages by scavenger-receptors and accelerate the formation of foam cells [[179]]. ALEs also exhibit several pro-inflammatory effects and are involved in the progression of atherosclerosis [[180]]. Both AGEs and ALEs were reported to accumulate in CKD [[181],[182],[183],[184],[185]].

Carbamylation is the fixation of isocyanic acid, derived from the decomposition of urea on amine groups of proteins. Protein carbamylation is associated with cardiovascular disease [[186]], mortality in CKD [[187],[188]] and can also affect lipoproteins [[75]] and promote atherosclerotic complications [[68],[189]] (Figure 3).

Myeloperoxydase (MPO) activity contributes to the formation of chlorinated [[64]] and nitrosilated [[65]] proteins or lipids that are correlated with poor cardiovascular outcomes [[62],[190]]. Its activity can also lead to the oxidation and modification of lipoproteins and especially the adduction of thiocyanate produced from the decomposition of urea [[67]]. In CKD and especially in hemodialysis, this activity is enhanced [[60],[61],[191],[192]]. Wada et al. showed that MPO expression is associated with aortic stenosis in hemodialysis (HD) patients [[193]].

4. Oxidized Lipids in CKD: Evidences of Toxicity

4.1. Cholesterol and Oxysterols

Cholesterol is a major component of cell membranes. Its presence in almost all of the cell membranes makes it a perfect target for ROS. There are four major products of ROS-mediated cholesterol oxidation: 7α,β-OOH-Cholesterol, 7α,β-OH-Cholesterol, 7-oxo-Cholesterol and 5,6-epoxy-Cholesterol. However, there are many other minor forms of oxysterols produced by non-radical pathways (5-α-OOH-Cholesterol, 6α,β-OOH-Cholesterol with singlet oxygen; 5,6β-epoxy-Cholesterol and ozone; 5,6-dichlorocholestane and HOCl from neutrophils) [[194]].

Oxysterols play a role in the set-up of atherosclerosis as several studies found them in fatty streaks, aortic or atherosclerotic plaques [[195],[196],[197]]. Oxysterols exhibited a pro-apoptotic effect on monocytes [[198],[199]], vascular cells (smooth muscle cells [[198],[200]], endothelial cells [[198],[201]]) and hepatocytes [[202]]. Particularly, 7-oxo-cholesterol and 7α,β-OH-Cholesterol triggered the major toxic effect [[198]] but other products such as 5,6-ep-oxy-Cholesterol also showed a potential pro-apoptotic effect [[201],[203]]. Other deleterious effects have been shown from various oxysterols including death of macrophages in latter stages of atherosclerosis [[204]], production of pro-inflammatory cytokines [[205],[206]], LDL oxidation [[207]] and platelet aggregation [[208]]. Nevertheless, their role in the modification of cholesterol metabolism still remains unclear [[194],[209]].

Oxysterols are metabolized by the liver and excreted as bile acids. In healthy subjects, oxysterols are found at very low plasma concentrations [[210]] (Table 1). These concentrations are significantly increased in CKD patients compared to a control population and especially in end-stage renal disease (ESRD) patients undergoing hemodialysis [[113],[114]]. Moreover, Siems et al. reported an increase of their concentration after an HD session [[114]].

4.2. Oxidized Phospholipids

Phospholipids (PLs) are the main components of cell membranes and, as cholesterol, are more exposed to oxidative stress and ROS. They also make up the external layer of lipoproteins and are a preferential site of oxidative and covalent modifications. Oxidized phospholipids can be produced through several pathways. Peroxyl radicals are derived from the free-radical-dependent oxidation of PUFAs esterified into PLs. [[211]]. Nitration can happen on PLs and generate nitrated-PUFAs and PLs [[212]]. Halogenation by a direct action of HOCl or HOBr released by neutrophilic and eosinophilic cells can also modify PLs by the addition of halogenide and hydroxyl groups leading to halohydrins (chlorydrins [[213]] and bromohydrins [[214]]) residues on PLs. Indeed, MPO and eosinophilic peroxidase activities are increased in CKD [[60],[61],[191],[192]]. Enzymatic pathways of oxidation are almost always associated with the activity of 12- and 15-lipoxygenases, leading to the formation of hydroperoxides residues on PLs either in cell membranes [[215]] or lipoproteins [[216],[217]].

These oxidized PLs (Ox-PLs) exhibit several biological effects [[218]]. First, they play a role in enhanced cell expression of adhesion molecules. Ox-PLs are involved in the activation of β1-integrin/fibronectin [[219],[220]] and P-selectin [[221],[222]] pathways of adhesion. Ox-PLs can also increase the generation of ROS by the elevation of the activity of NADPH oxidase [[223]]. As PLs are key activators of blood coagulation and platelet activation, Ox-PLs can also modulate this phenomenon. Effects on blood coagulation are mitigated as Ox-PLs can exert opposite effects on several steps of the coagulation cascade even if a pro-coagulation tendency raises from these studies [[224],[225],[226]]. Ox-PLs have shown pro-aggregate properties on platelets and vascular cells [[227],[228],[229],[230]]. Many others effects of Ox-PLs are described in the literature (smooth muscle cells, bone, pro-angiogenic properties…) [[211],[231]].

Part of Ox-PLs biological activity results from their binding to CD-36 receptor (a class B scavenger receptor) [[232],[233]]. This receptor is well-known for its implication in atherosclerosis [[69]] and its expression is increased in CKD patients [[70]].

Moreover, high OxPL/ApoB ratio has been related to severe coronary artery disease [[102]] in patients without CKD (mean level of about 0.20 and 0.15 for respectively <60 years and >60 years population). This ratio has been correlated with the presence and progression of carotid, femoral atherosclerosis and cardiovascular disease for a ratio value higger than 0.088 [[103]]. Interestingly, in ESRD patients undergoing HD, this mean ratio was found to be at 0.13 [[56]] (Table 1). Nevertheless, this ratio was not found to be associated with cardiovascular disease in hemodialysis patients [[56],[115]]. Indeed, their concentration decreases after an HD session [[56]]. This decrease may partially explain the absence of association in HD patients. This ratio has been also associated with renal progression in systemic lupus erythematous patients [[234]].

4.3. Fatty Acid Peroxidation Products (FAPP)

Fatty acids represent an important source of energy in human body physiology. Most of the time, they are derived from triglycerides or phospholipids and can be either saturated or unsaturated. Poly unsaturated fatty acids (PUFAs) are more prone to oxidation, and especially in CKD.

Malondialdehyde (MDA) is the result of polyunsaturated fatty acid oxidation containing more than two double bounds. More than a simple marker of lipid peroxidation, it covalently binds to proteins and nucleic acids, interfering with their normal biological functions. Indeed, MDA binding with nucleic acids can form several toxic adducts [[235]] and induce frameshift mutations and base-pair substitutions [[236]] (Figure 2 and Figure 3). Furthermore, MDA can react with lysine amino group and generate lysine-lysine bounds [[237]]. On ApoB, these bounds were associated with atherosclerosis [[238]]. MDA can be assayed itself or detected as a derived product of its reaction with thiobarbituric acid (TBA) that produces thiobarbituric acid reactive species (TBARS) [[239]]. Several studies have shown that MDA is elevated in CKD and represents a good marker of increased oxidative stress [[116],[165],[166],[240],[241],[242],[243],[244]]. Moreover, MDA (or TBARS) levels are correlated with GFR [[241]], creatinine levels [[245]] and intensity of renal damages [[166]]. Surprisingly, data on HD behavior of MDA concentration are controversial. In Kuchta et al. study, it was not affected by HD procedure [[162]]. In other reports, HD session triggered a significant decrease of the MDA concentration [[116],[117]] but was found to increase in a Nigerian cohort [[118]]. As an evidence of toxicity and as a significant part of MDA is excreted in the urine [[246]], EuTox group has already classified MDA as an uremic toxin [[9]].

Polyunsaturated fatty acids can also generate other reactive lipid aldehydes such as acrolein and 4-hydroxy-2-alkenals [[237]]. The latter, and particularly, 4-hydroxy-2-nonenal (4-HNE) (a by-product of the peroxidation of n-6 PUFAs) and 4-hydroxy-2-hexenal (4-HHE) (a by-product of the peroxidation of n-3 PUFAs) can react with proteins by a Michael addition mechanism (Figure 2). These adducts can especially bind to histidine, cysteine and lysine residues [[247]]. These ALEs disrupt several biological functions such as Na+/K+ ATPases [[248]], mitochondrial functions (potential role in permeability transition [[249]] and membrane fluidity [[250]]). These adducts are also found in large amounts in human atherosclerotic lesions [[251]]. Furthermore, HNE-modified LDL can activate macrophages and increase the up-regulation of class A scavenger receptors involved in the transformation of these cells into foam cells [[252]]. 4-HNE adducts induce smooth muscle cell proliferation in aortas of rats by the upregulation of ERK1 and ERK2 pathways [[253]]. 4-HNE can also alter vascular permeability and trigger apoptosis of endothelial cells [[254]] and promote the adhesion of pro-inflammatory cells to the endothelium [[255]]. There is some evidence that 4-HNE accumulates in CKD and especially in ESRD patients [[256]]. In a study by Sommerburg et al., mean level of 4-HNE was 3 fold higher in HD patients compared to healthy controls [[257]]. Alhamdani et al. showed that alkanals, alkenals and 4-hydroxy-alkenals concentrations are increased in HD patients compared to controls [[258]] (Table 1). Interestingly, HD procedure tends to reduce the 4-HNE concentration in several reports [[116],[119],[120]]. However, as the major part of 4-HNE reacts with proteins and creates stable adducts (ALEs), this observed reduction can over-estimate the decrease of the overall pool of 4-HNE in an HD session. As a major proof of toxicity and as part of alkenals are excreted in the urine [[121]], EuTox group has already classified 4-hydroxy-2-alkenals as a uremic toxins [[9]]. To the best of our knowledge, there is only limited data in the literature regarding the levels of 4-HHE in patients although its cytotoxic effect on proximal tubular cells was demonstrated in vitro [[259]].

4.4. F2-Isoprostanes

Arachidonic acid peroxidation generates F2-isoprostanes by a cyclo-oxygenase independent pathway [[260],[261],[262]]. Part of these isoprostanes is unesterified but a great majority remains esterified. 8-epi-PGF2α acts as an agonist/antagonist on platelet aggregation via Thromboxane A2 receptor (TxA2-R). Added at high concentrations, it directly induced platelet aggregation via TxA2-R whereas at low concentrations, it inhibited platelet aggregation. Thus, low amount of 8-epi-PGF2α acts as an antagonist of this receptor and inhibits platelet aggregation [[263]] induced by a TXA2 agonist. F2-isoprostanes promote endothelial cell proliferation and endothelin-1 secretion [[264]]. Moreover, these compounds have potential vasoconstrictive effects on smooth muscle cells [[265]]. Intra-arterial infusion of F2-isoprostanes led to a decrease in GFR and these effects were counteracted with TxA2-R antagonists [[266]]. Additionally, high containing-vitamin E diet in aged rats increased the GFR by 50% and reduced glomerular sclerosis concurrently with a reduction of F2-isoprostanes concentration [[267]]. Therefore, F2-Isoprostane accumulation may play a role in CKD progression [[10]], especially since its concentration is closely correlated with GFR [[8],[268]]. In addition, F2-isoprostane concentrations are elevated in HD patients in several studies [[119],[122],[123],[124],[125]] compared with intra-studies control groups and data from the literature [[269]] (Table 1) making them suitable for classification as uremic toxins and particularly because their concentrations decrease after kidney transplantation [[270],[271]]. Part of these F2-isoprostanes are cleared by the kidney [[126],[127]] but an HD session seems to have no effect on their concentration [[119],[128]].

5. Conclusions

CKD is associated with deep modifications in oxidative stress balance, lipid metabolism and turnover, which is responsible for an accumulation of various toxic forms of lipids and lipoproteins. EUtox defined a uremic toxin as an accumulated solute, normally excreted by the kidneys, that interacts negatively with biological functions. As these molecules accumulate in ESRD and exhibit many noxious effects on cell metabolism, CKD progression, cardiovascular system they can be regarded as uremic toxins even if they are not always excreted by the kidneys. Future efforts need to be concentrated on the enhancement of the removal of these lipids and the avoidance of their generation.



Figures were realized with Servier Medical Art under the terms of the Creative Commons Attributions 3.0 France license.


  1. A.S. GoG.M. ChertowD. FanC.E. McCullochC.-Y. HsuChronic kidney disease and the risks of death, cardiovascular events, and hospitalizationN. Engl. J. Med.20043511296130510.1056/NEJMoa04103115385656
  2. P.A. McCulloughV. AgrawalE. DanielewiczG.S. AbelaAccelerated atherosclerotic calcification and Monckeberg’s sclerosis: A continuum of advanced vascular pathology in chronic kidney diseaseClin. J. Am. Soc. Nephrol.200831585159810.2215/CJN.0193040818667741
  3. E.L. SchiffrinM.L. LipmanJ.F.E. MannChronic kidney disease: Effects on the cardiovascular systemCirculation2007116859710.1161/CIRCULATIONAHA.106.67834217606856
  4. M. CozzolinoD. BrancaccioM. GallieniE. SlatopolskyPathogenesis of vascular calcification in chronic kidney diseaseKidney Int.20056842943610.1111/j.1523-1755.2005.00421.x16014020
  5. S.M. MoeN.X. ChenPathophysiology of vascular calcification in chronic kidney diseaseCirc. Res.20049556056710.1161/01.RES.0000141775.67189.9815375022
  6. C.P. KovesdyB.K. TrivediJ.E. AndersonAssociation of kidney function with mortality in patients with chronic kidney disease not yet on dialysis: A historical prospective cohort studyAdv. Chronic Kidney Dis.20061318318810.1053/j.ackd.2006.01.00516580621
  7. P. MuntnerJ. HeB.C. AstorA.R. FolsomJ. CoreshTraditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: Results from the atherosclerosis risk in communities studyJ. Am. Soc. Nephrol.20051652953810.1681/ASN.200408065615625072
  8. E. DounousiE. PapavasiliouA. MakedouK. IoannouK.P. KatopodisA. TselepisK.C. SiamopoulosD. TsakirisOxidative stress is progressively enhanced with advancing stages of CKDAm. J. Kidney Dis.20064875276010.1053/j.ajkd.2006.08.01517059994
  9. F. DurantonG. CohenR. De SmetM. RodriguezJ. JankowskiR. VanholderA. Argileson behalf of the European Uremic Toxin Work GroupNormal and pathologic concentrations of uremic toxinsJ. Am. Soc. Nephrol.2012231258127010.1681/ASN.201112117522626821
  10. S. CottoneG. MulèM. GuarneriA. PalermoM.C. LoritoR. RiccobeneR. ArsenaF. VaccaroA. VadalàE. NardiEndothelin-1 and F2-isoprostane relate to and predict renal dysfunction in hypertensive patientsNephrol. Dial. Transplant.20092449750310.1093/ndt/gfn48918772174
  11. N.D. VaziriRole of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney diseaseClin. Exp. Nephrol.20141826526810.1007/s10157-013-0847-z23974528
  12. C. WannerV. KraneW. MärzM. OlschewskiJ.F.E. MannG. RufE. RitzGerman Diabetes and Dialysis Study InvestigatorsAtorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysisN. Engl. J. Med.200535323824810.1056/NEJMoa04354516034009
  13. B.C. FellströmA.G. JardineR.E. SchmiederH. HoldaasK. BannisterJ. BeutlerD.-W. ChaeA. ChevaileS.M. CobbeC. Grönhagen-RiskaRosuvastatin and cardiovascular events in patients undergoing hemodialysisN. Engl. J. Med.20093601395140710.1056/NEJMoa081017719332456
  14. P. BarterLipoprotein metabolism and CKD: OverviewClin. Exp. Nephrol.20141824324610.1007/s10157-013-0866-924052157
  15. N.D. VaziriK. NorrisLipid disorders and their relevance to outcomes in chronic kidney diseaseBlood Purif.20113118919610.1159/00032184521228589
  16. Z.A. MassyThe role of lipids and uremic toxins in cardiovascular disease in CKDClin. Exp. Nephrol.20141825525610.1007/s10157-013-0864-y24072415
  17. N.D. VaziriHDL abnormalities in nephrotic syndrome and chronic kidney diseaseNat. Rev. Nephrol.201512374710.1038/nrneph.2015.18026568191
  18. W.F. KeaneJ.E. TomassiniD.R. NeffLipid Abnormalities in Patients with Chronic Kidney Disease: Implications for the Pathophysiology of AtherosclerosisJ. Atheroscler. Thromb.20132012313310.5551/jat.1284923095239
  19. F. MaduellF. MoresoM. PonsR. RamosJ. Mora-MaciaJ. CarrerasJ. SolerF. TorresJ.M. CampistolA. Martinez-CastelaoHigh-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patientsJ. Am. Soc. Nephrol.20132448749710.1681/ASN.201208087523411788
  20. P.S. SeverB. DahlöfN.R. PoulterH. WedelG. BeeversPrevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trialLancet20033611149115812686036
  21. M. TonelliL. MoyeF.M. SacksB. KiberdPravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiencyAnn. Intern. Med.20031389810410.7326/0003-4819-138-2-200301210-0001012529091
  22. M. TonelliL. MoyéF.M. SacksT. ColeG.C. CurhanCholesterol and recurrent events trial investigatorsEffect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular diseaseJ. Am. Soc. Nephrol.2003141605161310.1097/01.ASN.0000068461.45784.2F12761262
  23. R. FathiN. IsbelL. ShortB. HaluskaD. JohnsonT.H. MarwickThe effect of long-term aggressive lipid lowering on ischemic and atherosclerotic burden in patients with chronic kidney diseaseAm. J. Kidney Dis.200443455210.1053/j.ajkd.2003.09.01214712426
  24. S.C. PalmerS.D. NavaneethanJ.C. CraigHMG CoA reductase inhibitors (statins) for dialysis patientsCochrane Database Syst. Rev.201310.1002/14651858.CD004289.pub5
  25. S.D. NavaneethanF. PansiniV. PerkovicHMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysisCochrane Database Syst. Rev.200910.1002/14651858.CD007784
  26. S.C. PalmerS.D. NavaneethanJ.C. CraigHMG CoA reductase inhibitors (statins) for kidney transplant recipientsCochrane Database Syst. Rev.201410.1002/14651858.CD005019.pub4
  27. H. OdaW.F. KeaneRecent advances in statins and the kidneyKidney Int.1999562510.1046/j.1523-1755.1999.07101.x
  28. C. ZojaD. CornaD. RottoliD. CattaneoC. ZanchiEffect of combining ACE inhibitor and statin in severe experimental nephropathyKidney Int.2002611635164510.1046/j.1523-1755.2002.00332.x11967013
  29. M.P. O’DonnellB.L. KasiskeY. KimD. AtluruW.F. KeaneLovastatin inhibits proliferation of rat mesangial cellsJ. Clin. Investig.199391838710.1172/JCI1162048423236
  30. J.C. BaeJ.M. HanS. KwonJ.H. JeeT.Y. YuM.K. LeeJ.H. KimLDL-C/apoB and HDL-C/apoA-1 ratios predict incident chronic kidney disease in a large apparently healthy cohortAtherosclerosis201625117017610.1016/j.atherosclerosis.2016.06.02927341533
  31. P.J. NestelN.H. FidgeM.H. TanIncreased lipoprotein-remnant formation in chronic renal failureN. Engl. J. Med.198230732933310.1056/NEJM1982080530706017088097
  32. M. OkuboH. HanadaM. MatsuiY. HidakaD. MasudaY. SakataS. YamashitaSerum apolipoprotein B-48 concentration is associated with a reduced estimated glomerular filtration rate and increased proteinuriaJ. Atheroscler. Thromb.20142197498210.5551/jat.2330924882621
  33. T. HayashiT. HiranoT. TairaA. TokunoY. MoriS. KobaM. AdachiRemarkable increase of apolipoprotein B48 level in diabetic patients with end-stage renal diseaseAtherosclerosis200819715415810.1016/j.atherosclerosis.2007.03.01517462654
  34. M. CofanF. CofanB. CamposR. GuerraJ.M. CampistolF. OppenheimerEffect of apolipoprotein B polymorphism in kidney transplantationTransplant. Proc.2005373794379510.1016/j.transproceed.2005.08.06216386541
  35. H. MoradiM.V. PahlR. ElahimehrN.D. VaziriImpaired antioxidant activity of high-density lipoprotein in chronic kidney diseaseTransl. Res.2009153778510.1016/j.trsl.2008.11.00719138652
  36. T. ShojiY. NishizawaH. NishitaniM. YamakawaImpaired metabolism of high density lipoprotein in uremic patientsKidney Int.1992411653166110.1038/ki.1992.2381501422
  37. N.D. VaziriK. LiangJ.S. ParksDown-regulation of hepatic lecithin: Cholesterol acyltransferase gene expression in chronic renal failureKidney Int.2001592192219610.1046/j.1523-1755.2001.00734.x11380821
  38. N.D. VaziriK. LiangDown-regulation of tissue lipoprotein lipase expression in experimental chronic renal failureKidney Int.1996501928193510.1038/ki.1996.5158943476
  39. N.D. VaziriX.Q. WangK. LiangSecondary hyperparathyroidism downregulates lipoprotein lipase expression in chronic renal failureAm. J. Physiol.1997273925930
  40. N.D. VaziriJ. YuanZ. NiS.B. NicholasK.C. NorrisLipoprotein lipase deficiency in chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1 expressionClin. Exp. Nephrol.20121623824310.1007/s10157-011-0549-322009636
  41. C. KimN.D. VaziriDown-regulation of hepatic LDL receptor-related protein (LRP) in chronic renal failureKidney Int.2005671028103210.1111/j.1523-1755.2005.00166.x15698441
  42. Y. HirowatariY. HommaJ. YoshizawaK. HommaIncrease of electronegative-LDL-fraction ratio and IDL-cholesterol in chronic kidney disease patients with hemodialysis treatmentLipids Health Dis.201211110.1186/1476-511X-11-11122221411
  43. M. KlinM. SmogorzewskiZ. NiG. ZhangAbnormalities in hepatic lipase in chronic renal failure: Role of excess parathyroid hormoneJ. Clin. Investig.1996972167217310.1172/JCI1186578636395
  44. K. LiangN.D. VaziriDown-regulation of hepatic lipase expression in experimental nephrotic syndromeKidney Int.1997511933193710.1038/ki.1997.2639186885
  45. T. SatoK. LiangN.D. VaziriProtein restriction and AST-120 improve lipoprotein lipase and VLDL receptor in focal glomerulosclerosisKidney Int.2003641780178610.1046/j.1523-1755.2003.00281.x14531811
  46. K. LiangN.D. VaziriAcquired VLDL receptor deficiency in experimental nephrosisKidney Int.1997511933193710.1038/ki.1997.2639186885
  47. T. SatoK. LiangN.D. VaziriDown-regulation of lipoprotein lipase and VLDL receptor in rats with focal glomerulosclerosisKidney Int.2002641780178610.1046/j.1523-1755.2003.00281.x14531811
  48. N.D. VaziriDyslipidemia of chronic renal failure: The nature, mechanisms, and potential consequencesAm. J. Physiol. Ren. Physiol.200629026227210.1152/ajprenal.00099.200516403839
  49. P. DeGouletM. LeGrainI. ReachF. AimeC. DevriesP. RojasC. JacobsMortality risk factors in patients treated by chronic hemodialysisNephron19823110311010.1159/0001826277121651
  50. E.G. LowrieN.L. LewDeath risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilitiesAm. J. Kidney Dis.19901545848210.1016/S0272-6386(12)70364-52333868
  51. Y. LiuJ. CoreshJ.A. EustaceJ.C. LongeneckerB. JaarN.E. FinkR.P. TracyN.R. PoweM.J. KlagAssociation between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutritionJAMA200429145145910.1001/jama.291.4.45114747502
  52. I. LevitanS. VolkovOxidized LDL: Diversity, patterns of recognition, and pathophysiologyAntioxid. Redox201013397510.1089/ars.2009.273319888833
  53. S. RibeiroM.D.S. FariaG. SilvaH. NascimentoP. Rocha-PereiraV. MirandaE. VieiraR. SantosD. MendonçaA. QuintanilhaOxidized low-density lipoprotein and lipoprotein(a) levels in chronic kidney disease patients under hemodialysis: Influence of adiponectin and of a polymorphism in the apolipoprotein(a) geneHemodial. Int.20121648149010.1111/j.1542-4758.2012.00687.x22515595
  54. E.C. SamouilidouA.P. KarpouzaV. KostopoulosT. BakirtziK. PanteliasD. PetrasH. Tzanatou-ExarchouE. GrapsaLipid abnormalities and oxidized LDL in chronic kidney disease patients on hemodialysis and peritoneal dialysisRen. Fail.20123416016410.3109/0886022X.2011.64151522172020
  55. J. LoboF. SantosD. GrossoR. LimaA.L. BarreiraM. Leite Jr.D. MafraD.S.P. AbdallaElectronegative LDL and lipid abnormalities in patients undergoing hemodialysis and peritoneal dialysisNephron Clin. Pract.200810829830410.1159/00012798218434752
  56. M. BossolaL. TazzaE. MerkiS. GiungiG. LucianiE.R. MillerE.B. LinA. TortorelliS. TsimikasOxidized low-density lipoprotein biomarkers in patients with end-stage renal failure: Acute effects of hemodialysisBlood Purif.20072545746510.1159/00011246518075247
  57. D. DrożdżP. KwintaK. SztefkoZ. KordonT. DrożdżM. ŁątkaM. MiklaszewskaK. ZachwiejaA. RudzińskiJ.A. PietrzykOxidative stress biomarkers and left ventricular hypertrophy in children with chronic kidney diseaseOxid. Med. Cell. Longev.201610.1155/2016/752023126885251
  58. T. TakenakaK. TakahashiT. KobayashiE. OshimaS. IwasakiH. SuzukiOxidized low density lipoprotein (Ox-LDL) as a marker of atherosclerosis in hemodialysis (HD) patientsClin. Nephrol.200258333710.5414/CNP5803312141404
  59. K. PawlakM. MyśliwiecD. PawlakOxidized LDL to autoantibodies against oxLDL ratio—The new biomarker associated with carotid atherosclerosis and cardiovascular complications in dialyzed patientsAtherosclerosis201222425225710.1016/j.atherosclerosis.2012.07.01122840691
  60. K. Kalantar-ZadehM.-L. BrennanS.L. HazenSerum myeloperoxidase and mortality in maintenance hemodialysis patientsAm. J. Kidney Dis.200648596810.1053/j.ajkd.2006.03.04716797387
  61. C. KitabayashiT. NarukoK. SugiokaK. YunokiM. NakagawaM. InabaM. OhsawaY. KonishiM. ImanishiT. InouePositive association between plasma levels of oxidized low-density lipoprotein and myeloperoxidase after hemodialysis in patients with diabetic end-stage renal diseaseHemodial. Int.20131755756710.1111/hdi.1204923627905
  62. S.L. HazenJ.W. Heinecke3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intimaJ. Clin. Investig.1997992075208110.1172/JCI1193799151778
  63. A. PirilloG.D. NorataA.L. CatapanoLOX-1, OxLDL, and AtherosclerosisMediat. Inflamm.2013201311210.1155/2013/15278623935243
  64. J. HimmelfarbM.E. McMenaminG. LosetoJ.W. HeineckeMyeloperoxidase-catalyzed 3-chlorotyrosine formation in dialysis patientsFree Radic. Biol. Med.2001311163116910.1016/S0891-5849(01)00697-911705694
  65. E.A. PodrezD. SchmittH.F. HoffS.L. HazenMyeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitroJ. Clin. Investig.19991031547156010.1172/JCI554910359564
  66. S.W.M. ShiuS.M. XiaoY. WongW.S. ChowK.S.L. LamK.C.B. TanCarbamylation of LDL and its relationship with myeloperoxidase in Type 2 diabetes mellitusClin. Sci.201312617518110.1042/CS2013036923905837
  67. M. ExnerM. HermannR. HofbauerB. HartmannS. KapiotisB. GmeinerThiocyanate catalyzes myeloperoxidase-initiated lipid oxidation in LDLFree Radic. Biol. Med.20043714615510.1016/j.freeradbiomed.2004.04.03915203186
  68. E.O. ApostolovE. OkS. BurnsS. NawazA. SavenkaS.V. ShahA.G. BasnakianCarbamylated-oxidized LDL: Proatherosclerotic effects on endothelial cells and macrophagesJ. Atheroscler. Thromb.20132087889210.5551/jat.1403524067603
  69. Y.M. ParkCD36, a scavenger receptor implicated in atherosclerosisExp. Mol. Med.201446e9910.1038/emm.2014.3824903227
  70. M. ChmielewskiE. BrylL. MarzecE. AleksandrowiczJ.M. WitkowskiB. RutkowskiExpression of scavenger receptor CD36 in chronic renal failure patientsArtif. Organs20052960861410.1111/j.1525-1594.2005.29097.x16048476
  71. J. CarracedoA. MerinoC. BricenoS. SorianoP. BuendiaL. CallerosM. RodriguezA. Martin-MaloP. AljamaR. RamirezCarbamylated low-density lipoprotein induces oxidative stress and accelerated senescence in human endothelial progenitor cellsFASEB J.2011251314132210.1096/fj.10-17337721228221
  72. T. SpeerF.O. OwalaE.W. HolyS. ZewingerF.L. FrenzelB.E. StähliM. RazaviS. TriemH. CvijaL. RohrerCarbamylated low-density lipoprotein induces endothelial dysfunctionEur. Heart J.2014353021303210.1093/eurheartj/ehu11124658767
  73. E.W. HolyA. AkhmedovT. SpeerG.G. CamiciS. ZewingerN. BonettiJ.H. BeerT.F. LüscherF.C. TannerCarbamylated low-density lipoproteins induce a prothrombotic state via lox-1: Impact on arterial thrombus formation in vivoJ. Am. Coll. Cardiol.2016681664167610.1016/j.jacc.2016.07.75527712780
  74. J.N. SonY. LhoS. ShinS.-H. KwonK.C. MoonE. HaCarbamylated low-density lipoprotein increases reactive oxygen species (ROS) and apoptosis via lectin-like oxidized LDL receptor (LOX-1) mediated pathway in human umbilical vein endothelial cellsInt. J. Cardiol.201114642843010.1016/j.ijcard.2010.10.09821094547
  75. E.O. ApostolovD. RayA.V. SavenkaS.V. ShahA.G. BasnakianChronic Uremia Stimulates LDL Carbamylation and AtherosclerosisJ. Am. Soc. Nephrol.2010211852185710.1681/ASN.201004036520947625
  76. E.O. ApostolovA.G. BasnakianE. OkS.V. ShahCarbamylated low-density lipoprotein: Nontraditional risk factor for cardiovascular events in patients with chronic kidney diseaseJ. Ren. Nutr.20122213413810.1053/j.jrn.2011.10.02322200430
  77. V.S. KamannaM.L. KashyapR. PaiD.T. BuiUremic serum subfraction inhibits apolipoprotein AI production by a human hepatoma cell lineJ. Am. Soc. Nephrol.199451932007993998
  78. G.M. ShahZ.L. LinV.S. KamannaR. PaiB. BassaEffect of serum subfractions from peritoneal dialysis patients on Hep-G2 cell apolipoprotein AI and B metabolismKidney Int.1996502079208710.1038/ki.1996.5328943493
  79. B. ShaoM.N. OdaJ.F. OramJ.W. HeineckeMyeloperoxidase: An inflammatory enzyme for generating dysfunctional high density lipoproteinCurr. Opin. Cardiol.20062132232810.1097/01.hco.0000231402.87232.aa16755201
  80. K. LiangN.D. VaziriUpregulation of acyl-CoA: Cholesterol acyltransferase in chronic renal failureAm. J. Physiol. Endocrinol. Metab.200228367668110.1152/ajpendo.00364.200112217884
  81. M. HolzerG. SchilcherS. CurcicM. TriebS. LjubojevicT. StojakovicH. ScharnaglC.M. KopeckyA.R. RosenkranzA. HeinemannDialysis modalities and HDL composition and functionJ. Am. Soc. Nephrol.2015262267227610.1681/ASN.201403030925745027
  82. B. HewingS. ParathathT. BarrettW.K.K. ChungY.M. AstudilloT. HamadaB. RamkhelawonT.C. TallantM.S.S. YusufishaqJ.A. DiDonatoEffects of native and myeloperoxidase-modified apolipoprotein A-I on reverse cholesterol transport and atherosclerosis in miceArterioscler. Thromb. Vasc. Biol.20143477978910.1161/ATVBAHA.113.30304424407029
  83. B. ShaoC. TangA. SinhaP.S. MayerG.D. DavenportN. BrotM.N. OdaX.-Q. ZhaoJ.W. HeineckeHumans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidaseCirc. Res.20141141733174210.1161/CIRCRESAHA.114.30345424647144
  84. M. HolzerK. ZanggerD. El-GamalV. BinderS. CurcicV. KonyaR. SchuligoiA. HeinemannG. MarscheMyeloperoxidase-derived chlorinating species induce protein carbamylation through decomposition of thiocyanate and urea: Novel pathways generating dysfunctional high-density lipoproteinAntioxid. Redox Signal.2012171043105210.1089/ars.2011.440322462773
  85. M. HolzerM. GausterT. PfeiferC. WadsackG. FaulerP. StieglerH. KoefelerE. BeublerR. SchuligoiA. HeinemannProtein carbamylation renders high-density lipoprotein dysfunctionalAntioxid. Redox Signal.2011142337234610.1089/ars.2010.364021235354
  86. A. UndurtiY. HuangJ.A. LupicaJ.D. SmithJ.A. DiDonatoS.L. HazenModification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particleJ. Biol. Chem.2009284308253083510.1074/jbc.M109.04760519726691
  87. H. HondaM. UedaS. KojimaS. MashibaT. MichihataK. TakahashiK. ShishidoT. AkizawaOxidized high-density lipoprotein as a risk factor for cardiovascular events in prevalent hemodialysis patientsAtherosclerosis201222049350110.1016/j.atherosclerosis.2011.10.03822119537
  88. K. Kalantar-ZadehJ.D. KoppleN. KamranpourA.M. FogelmanM. NavabHDL-inflammatory index correlates with poor outcome in hemodialysis patientsKidney Int.2007721149115610.1038/
  89. M. HolzerR. Birner-GruenbergerT. StojakovicD. El-GamalV. BinderC. WadsackA. HeinemannG. MarscheUremia Alters HDL Composition and FunctionJ. Am. Soc. Nephrol.2011221631164110.1681/ASN.201011114421804091
  90. A. MangéA. GouxS. BadiouL. PatrierB. CanaudT. MaudelondeJ.-P. CristolJ. SolassolHDL proteome in hemodialysis patients: A quantitative nanoflow liquid chromatography-tandem mass spectrometry approachPLoS ONE201210.1371/journal.pone.003410722470525
  91. A.V. KheraM. CuchelM. la Llera-MoyaA. RodriguesM.F. BurkeK. JafriB.C. FrenchJ.A. PhillipsM.L. MucksavageR.L. WilenskyCholesterol efflux capacity, high-density lipoprotein function, and atherosclerosisN. Engl. J. Med.201136412713510.1056/NEJMoa100168921226578
  92. C. KopeckyM. HaidingerR. Birner-GrunbergerB. DarnhoferC.C. KalteneckerG. MarscheM. HolzerT. WeichhartM. AntlangerJ.J. KovarikRestoration of Renal Function Does Not Correct Impairment of Uremic HDL PropertiesJ. Am. Soc. Nephrol.20152656557510.1681/ASN.201311121925071090
  93. R. KasedaK. JabsT.E. HunleyD. JonesA. BianR.M. AllenK.C. VickersP.G. YanceyM.F. LintonS. FazioDysfunctional high-density lipoproteins in children with chronic kidney diseaseMetabolism20156426327310.1016/j.metabol.2014.10.02025467845
  94. S. YamamotoP.G. YanceyT.A. IkizlerW.G. JeromeR. KasedaB. CoxA. BianA. ShintaniA.B. FogoM.R.F. LintonDysfunctional high-density lipoprotein in patients on chronic hemodialysisJ. Am. Coll. Cardiol.2012602372237910.1016/j.jacc.2012.09.01323141484
  95. R. ShroffT. SpeerS. ColinM. CharakidaS. ZewingerB. StaelsG. Chinetti-GbaguidiI. HettrichL. RohrerF. O’NeillHDL in children with ckd promotes endothelial dysfunction and an abnormal vascular phenotypeJ. Am. Soc. Nephrol.2014252658266810.1681/ASN.201311121224854267
  96. C. KopeckyS. EbtehajB. GenserC. DrechslerV. KraneM. AntlangerJ.J. KovarikC.C. KalteneckerM. ParviziC. WannerHDL cholesterol efflux does not predict cardiovascular risk in hemodialysis patientsJ. Am. Soc. Nephrol.2016in press10.1681/ASN.201603026227612996
  97. T. KimuraK. SatoE. MalchinkhuuH. TomuraK. TamamaA. KuwabaraM. MurakamiF. OkajimaHigh-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptorsArterioscler. Thromb. Vasc. Biol.2003231283128810.1161/01.ATV.0000079011.67194.5A12775579
  98. D. LitvinovH. MahiniM. GarelnabiAntioxidant and anti-inflammatory role of paraoxonase 1: Implication in arteriosclerosis diseasesN. Am. J. Med. Sci.2012452353223181222
  99. T.F. DantoineJ. DebordJ.P. CharmesL. MerleP. MarquetG. LachatreC. Leroux-RobertDecrease of serum paraoxonase activity in chronic renal failureJ. Am. Soc. Nephrol.19989208220889808094
  100. D.J. KennedyW.H.W. TangY. FanY. WuS. MannM. PepoyS.L. HazenDiminished antioxidant activity of high-density lipoprotein-associated proteins in chronic kidney diseaseJ. Am. Heart Assoc.201310.1161/JAHA.112.00010423557751
  101. K. KotaniS. KimuraA. GugliucciParaoxonase-1 and ischemia-modified albumin in patients with end-stage renal diseaseJ. Physiol. Biochem.20116743744110.1007/s13105-011-0092-421484479
  102. S. TsimikasE.S. BrilakisE.R. MillerJ.P. McConnellR.J. LennonK.S. KornmanJ.L. WitztumP.B. BergerOxidized phospholipids, Lp(a) lipoprotein, and coronary artery diseaseN. Engl. J. Med.2005353465710.1056/NEJMoa04317516000355
  103. S. TsimikasS. KiechlJ. WilleitM. MayrE.R. MillerF. KronenbergQ. XuC. BergmarkS. WegerF. OberhollenzerOxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: Five-year prospective results from the Bruneck studyJ. Am. Coll. Cardiol.2006472219222810.1016/j.jacc.2006.03.00116750687
  104. S. TsimikasJ.L. HallLipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: A rationale for increased efforts to understand its pathophysiology and develop targeted therapiesJ. Am. Coll. Cardiol.20126071672110.1016/j.jacc.2012.04.03822898069
  105. S. TsimikasN.J. VineyS.G. HughesW. SingletonM.J. GrahamB.F. BakerJ.L. BurkeyQ. YangS.M. MarcovinaR.S. GearyAntisense therapy targeting apolipoprotein(a): A randomised, double-blind, placebo-controlled phase 1 studyLancet20153861472148310.1016/S0140-6736(15)61252-126210642
  106. B. KolleritsC. DrechslerV. KraneC. LaminaW. MärzH. DieplingerE. RitzC. WannerF. KronenbergGerman Diabetes and Dialysis Study InvestigatorsLipoprotein(a) concentrations, apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: Results from the 4D StudyNephrol. Dial. Transplant.2016311901190810.1093/ndt/gfv42826754832
  107. T.X. PedersenS.P. McCormickS. TsimikasS. BroL.B. NielsenLipoprotein(a) accelerates atherosclerosis in uremic miceJ. Lipid Res.2010512967297510.1194/jlr.M00674220584868
  108. M.E. FrischmannF. KronenbergE. TrenkwalderJ.R. SchaeferH. SchweerB. DieplingerP. KoenigK. IkewakiH. DieplingerIn vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patientsKidney Int.2007711036104310.1038/
  109. H.A. TzanatosB. AgroyannisC. ChondrosA. KapetanakiC. FourtounasL. SoubassiI. KopeliasCytokine release and serum lipoprotein (a) alterations during hemodialysisArtif. Organs20002432933310.1046/j.1525-1594.2000.06483.x10848673
  110. M.G. De Sain-Van Der VeldenD.J. ReijngoudG.A. KaysenM.M. GadellaaH. VoorbijF. StellaardH.A. KoomansT.J. RabelinkEvidence for increased synthesis of lipoprotein(a) in the nephrotic syndromeJ. Am. Soc. Nephrol.19989147414819697670
  111. F. KronenbergP. KönigU. NeyerM. AuingerA. PribasnigU. LangJ. ReitingerG. PinterG. UtermannH. DieplingerMulticenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysisJ. Am. Soc. Nephrol.199561101207579063
  112. F. KronenbergCauses and consequences of lipoprotein(a) abnormalities in kidney diseaseClin. Exp. Nephrol.20141823423710.1007/s10157-013-0875-824129557
  113. M. BoazL. IulianoJ. HimmelfarbZ. MatasF. MichelettaE. McMonagleV. FriedmanS. NatoliG. GvirtzA. BiroBaseline oxysterols and other markers of oxidative stress, inflammation and malnutrition in the Vitamin E and Intima media thickness Progression in End-stage Renal disease (VIPER) cohortNephron Clin. Pract.200510011111910.1159/00008529015849477
  114. W. SiemsS. QuastD. PeterW. AugustinF. CarluccioT. GruneA. SevanianH. HamplI. WiswedelOxysterols are increased in plasma of end-stage renal disease patientsKidney Blood Press. Res.20052830230610.1159/00009113316534225
  115. M. BossolaL. TazzaG. LucianiA. TortorelliS. TsimikasOxPL/apoB, lipoprotein(a) and OxLDL biomarkers and cardiovascular disease in chronic hemodialysis patientsJ. Nephrol.20112458158810.5301/JN.2011.644221404224
  116. E. SamouilidouE. GrapsaEffect of dialysis on plasma total antioxidant capacity and lipid peroxidation products in patients with end-stage renal failureBlood Purif.20032120921210.1159/00007069112784045
  117. J.M. NúñezZ. GhaisJ. BustamanteEvaluation of oxidant-antioxidant balance in patients on maintenance haemodialysis: A comparative study of dialyzers membranesNephron Clin. Pract.20101146773
  118. M.O. AjalaP.S. OgunroA. OdunEffect of hemodialysis on total antioxidant status of chronic renal failure patients in government hospitals in Lagos NigeriaNiger J. Clin. Pract.20111415415821860130
  119. I. WiswedelD. PeterA. GardemannF. CarluccioH. HamplW. SiemsSerum concentrations of F2-isoprostanes and 4-Hydroxynonenal in hemodialysis patients in relation to inflammation and renal anemiaBiomark. Insights2008341942819578522
  120. P. OdettiN. TraversoF. MonacelliS. MeniniJ. VazzanaB. TassoM.A. PronzatoC. RobaudoG. DeferrariVitamin E-coated filter decreases levels of free 4-hydroxyl-2-nonenal during haemodialysis sessionsFree Radic. Res.20064020721210.1080/1071576050044512116390830
  121. M. GuichardantS. BacotP. MoliereM. LagardeHydroxy-alkenals from the peroxidation of n-3 and n-6 fatty acids and urinary metabolitesProstaglandins Leukot. Essent. Fat. Acids20067517918210.1016/j.plefa.2006.05.00616828271
  122. G.J. HandelmanM.F. WalterR. AdhikarlaJ. GrossG.E. DallalN.W. LevinJ.B. BlumbergElevated plasma F2-isoprostanes in patients on long-term hemodialysisKidney Int.2001591960196610.1046/j.1523-1755.2001.0590051960.x11318969
  123. T.A. IkizlerJ.D. MorrowL.J. RobertsJ.A. EvansonB. BeckerR.M. HakimY. ShyrJ. HimmelfarbPlasma F2-isoprostane levels are elevated in chronic hemodialysis patientsClin. Nephrol.20025819019710.5414/CNP5819012356187
  124. J. HimmelfarbS. PhinneyT.A. IkizlerJ. KaneE. McMonagleG. MillerGamma-tocopherol and docosahexaenoic acid decrease inflammation in dialysis patientsJ. Ren. Nutr.20071729630410.1053/j.jrn.2007.05.01117720098
  125. M. KamgarF. ZaldivarN.D. VaziriM.V. PahlAntioxidant therapy does not ameliorate oxidative stress and inflammation in patients with end-stage renal diseaseJ. Natl. Med. Assoc.200910133634410.1016/S0027-9684(15)30881-619397224
  126. S.M. HarmanL. LiangP.D. TsitourasF. GucciardoC.B. HewardP.D. ReavenW. PingA. AhmedR.G. CutlerUrinary excretion of three nucleic acid oxidation adducts and isoprostane F(2)alpha measured by liquid chromatography-mass spectrometry in smokers, ex-smokers, and nonsmokersFree Radic. Biol. Med.2003351301130910.1016/j.freeradbiomed.2003.07.00314607529
  127. J.D. MorrowW.E. ZackertJ.P. YangE.H. KurhtsD. CallewaertR. DworskiK. KanaiD. TaberK. MooreJ.A. OatesQuantification of the major urinary metabolite of 15-F2t-isoprostane (8-iso-PGF2α) by a stable isotope dilution mass spectrometric assayAnal. Biochem.199926932633110.1006/abio.1999.400810222005
  128. M. MorenaI. JaussentL. ChalabiA.-S. BargnouxA.-M. DupuyS. BadiouC. RakicM. ThomasB. CanaudJ.-P. CristolBiocompatibility of heparin-grafted hemodialysis membranes: Impact on monocyte chemoattractant protein-1 circulating level and oxidative statusHemodial. Int.20101440341010.1111/j.1542-4758.2010.00494.x20955273
  129. F. BonominiS. TengattiniA. FabianoR. BianchiAtherosclerosis and oxidative stressHistol. Histopathol.20082338139018072094
  130. E. CadenasK.J.A. DaviesMitochondrial free radical generation, oxidative stress, and agingFree Radic. Biol. Med.20002922223010.1016/S0891-5849(00)00317-811035250
  131. P.V. VignaisThe superoxide-generating NADPH oxidase: Structural aspects and activation mechanismCell. Mol. Life Sci.2002591428145910.1007/s00018-002-8520-912440767
  132. S. De MinicisR. BatallerD.A. BrennerNADPH oxidase in the liver: Defensive, offensive, or fibrogenic?Gastroenterology200613127227510.1053/j.gastro.2006.05.04816831609
  133. E. NovoM. ParolaRedox mechanisms in hepatic chronic wound healing and fibrogenesisFibrogenesis Tissue Repair20081110.1186/1755-1536-1-519014647
  134. J.D. LambethNox enzymes, ROS, and chronic disease: An example of antagonistic pleiotropyFree Radic. Biol. Med.20074333234710.1016/j.freeradbiomed.2007.03.02717602948
  135. D. GrottoL.D. Santa MariaS. BoeiraJ. ValentiniM.F. CharãoA.M. MoroP.C. NascimentoV.J. PomblumS.C. GarciaRapid quantification of malondialdehyde in plasma by high performance liquid chromatography-visible detectionJ. Pharm. Biomed. Anal.20074361962410.1016/j.jpba.2006.07.03016949242
  136. M. GuichardantB. ChantegrelC. DeshayesA. DoutheauP. MoliereM. LagardeSpecific markers of lipid peroxidation issued from n-3 and n-6 fatty acidsBiochem. Soc. Trans.20043213914010.1042/bst032013914748733
  137. L.L. SmithB.H. JohnsonBiological activities of oxysterolsFree Radic. Biol. Med.1989728533210.1016/0891-5849(89)90136-62673947
  138. T. FinkelN.J. HolbrookOxidants, oxidative stress and the biology of ageingNature20004823924710.1038/3504168711089981
  139. T.J. PetersAll about AlbuminAcademic Press, Inc.San Diego, CA, USA1996
  140. C. JacobsenLysine residue 240 of human serum albumin is involved in high-affinity binding of bilirubinBiochem. J.197817145345910.1042/bj1710453656055
  141. J. NeužilR. StockerBilirubin attenuates radical-mediated damage to serum albuminFEBS Lett.199333128128410.1016/0014-5793(93)80353-V8375511
  142. J. NeužilR. StockerFree and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidationJ. Biol. Chem.199426916712167198206992
  143. J.M.C. GutteridgeAntioxidant properties of the proteins caeruloplasmin, albumin and transferrin. A study of their activity in serum and synovial fluid from patients with rheumatoid arthritisBiochim. Biophys. Acta198686911912710.1016/0167-4838(86)90286-43942755
  144. K. OettlR.E. StauberPhysiological and pathological changes in the redox state of human serum albumin critically influence its binding propertiesBr. J. Pharmacol.200715158059010.1038/sj.bjp.070725117471184
  145. L. Del VecchioF. LocatelliM. CariniWhat we know about oxidative stress in patients with chronic kidney disease on dialysis—Clinical effects, potential treatment, and preventionSemin. Dial.201124566410.1111/j.1525-139X.2010.00819.x21299632
  146. P.S. TuckerV.J. DalboT. HanM.I. KingsleyClinical and research markers of oxidative stress in chronic kidney diseaseBiomarkers20131810311510.3109/1354750X.2012.74930223339563
  147. V. LaheraM. GoicoecheaS.G. de VinuesaP. OubiñaV. CachofeiroF. Gómez-CampderáR. AmannJ. LuñoOxidative stress in uremia: The role of anemia correctionJ. Am. Soc. Nephrol.200617S174S17710.1681/ASN.200608091117130258
  148. B.B. RatliffW. AbdulmahdiR. PawarM.S. WolinOxidant mechanisms in renal injury and diseaseAntioxid. Redox Signal.20162511914610.1089/ars.2016.666526906267
  149. C.-T. ChaoC.-K. ChiangUremic toxins, oxidative stress, and renal fibrosis: An interwined complexJ. Ren. Nutr.20152515515910.1053/j.jrn.2014.10.01025511523
  150. A. ModaresiM. NafarZ. SahraeiOxidative stress in chronic kidney diseaseIran. J. Kidney Dis.2015916517925957419
  151. A. PopoloG. AutoreA. PintoS. MarzoccoOxidative stress in patients with cardiovascular disease and chronic renal failureFree Radic. Res.20134734635610.3109/10715762.2013.77937323438723
  152. C. LibettaV. SepeP. EspositoF. GalliA. Dal CantonOxidative stress and inflammation: Implications in uremia and hemodialysisClin. Biochem.2011441189119810.1016/j.clinbiochem.2011.06.98821777574
  153. N.D. VaziriOxidative stress in uremia: Nature, mechanisms, and potential consequencesSemin. Nephrol.20042446947310.1016/j.semnephrol.2004.06.02615490413
  154. J. HimmelfarbP. StenvinkelT.A. IkizlerR.M. HakimThe elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremiaKidney Int.2002621524153810.1046/j.1523-1755.2002.00600.x12371953
  155. L.F. RamosA. ShintaniT.A. IkizlerJ. HimmelfarbOxidative stress and inflammation are associated with adiposity in moderate to severe CKDJ. Am. Soc. Nephrol.20081959359910.1681/ASN.200703035518256365
  156. Y. HigashiS. SasakiK. NakagawaH. MatsuuraT. OshimaK. ChayamaEndothelial function and oxidative stress in renovascular hypertensionN. Engl. J. Med.20023461954196210.1056/NEJMoa01359112075056
  157. R.M. TouyzReactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: What is the clinical significance?Hypertension20044424825210.1161/01.HYP.0000138070.47616.9d15262903
  158. G. ZalbaG. San JoséM.U. MorenoM.A. FortuñoA. FortuñoF.J. BeaumontJ. DíezOxidative stress in arterial hypertension: Role of NAD(P)H oxidaseHypertension2001381395139910.1161/hy1201.09961111751724
  159. A. MohN. SakataS. TakebayashiK. TateishiR. NagaiS. HoriuchiJ. ChiharaIncreased production of urea hydrogen peroxide from Maillard reaction and a UHP-Fenton pathway related to glycoxidation damage in chronic renal failureJ. Am. Soc. Nephrol.2004151077108510.1097/01.ASN.0000121841.82093.0915034112
  160. I.G. FatourosP. PasadakisA. SovatzidisAcute exercise may exacerbate oxidative stress response in hemodialysis patientsNephron Clin. Pract.2008109556410.1159/00013999018560239
  161. S. CoaccioliM.L. StandoliR. BiondiA. PanaccioneP. LanducciR. Del GiornoA. PaladiniM. StandoliA. PuxedduOpen comparison study of oxidative stress markers between patients with chronic renal failure in conservative therapy and patients in haemodialysisClin. Ter.201016143543920949239
  162. A. KuchtaA. PacanisB. Kortas-StempakA. ÇwiklińskaM. ZiętkiewiczM. RenkeB. RutkowskiEstimation of oxidative stress markers in chronic kidney diseaseKidney Blood Press. Res.201134121910.1159/00032150821071957
  163. S. BiasioliR. SchiavonL. PetrosinoL. CavalliniE. De FantiA. ZambelloD. BorinL. TargaDo different dialytic techniques have different atherosclerotic and antioxidant activities?ASAIO J.20014751652110.1097/00002480-200109000-0002411575829
  164. R. Shurtz-SwirskiE. MashiachB. KristalT. ShkolnikS.M. ShashaAntioxidant enzymes activity in polymorphonuclear leukocytes in chronic renal failureNephron19957117617910.1159/0001887088569950
  165. A. AtamerY. KocyigitS.A. EcderS. SelekN. IihanEffect of oxidative stress on antioxidant enzyme activities, homocysteine and lipoproteins in chronic kidney diseaseJ. Nephrol.20082192493019034878
  166. H.-T. KuoM.-C. KuoY.-W. ChiuJ.-M. ChangJ.-Y. GuhH.-C. ChenIncreased glomerular and extracellular malondialdehyde levels in patients and rats with focal segmental glomerulosclerosisEur. J. Clin. Investig.20053524525010.1111/j.1365-2362.2005.01488.x15816993
  167. M. InalG. KanbakS. SenF. AkyüzE. SunalAntioxidant status and lipid peroxidation in hemodialysis patients undergoing erythropoietin and erythropoietin-vitamin E combined therapyFree Radic. Res.19993121121610.1080/1071576990030077110499778
  168. A. VuralM.I. YilmazK. CaglarA. AydinA. SonmezT. EyiletenC. AcikelB. GulecO. KozakK. OnerAssessment of oxidative stress in the early posttransplant period: Comparison of cyclosporine A and tacrolimus-based regimensAm. J. Nephrol.20052525025510.1159/00008607915925859
  169. L. OngajoothS. OngajyoothA. LikidlilidY. ChantachumC. ShayakulS. NilwarangkurRole of lipid peroxidation, trace elements and anti-oxidant enzymes in chronic renal disease patientsJ. Med. Assoc. Thail.1996797918009071084
  170. M. RomeuR. NoguesL. MarcasV. Sánchez-MartosM. MuleroA. Martinez-VeaJ. MallolM. GiraltEvaluation of oxidative stress biomarkers in patients with chronic renal failure: A case control studyBMC Res. Notes201032010.1186/1756-0500-3-2020181004
  171. P. RutkowskiS. MalgorzewiczE. SlominskaInterrelationship between uremic toxicity and oxidative stressJ. Ren. Nutr.20061619019310.1053/j.jrn.2006.04.00816825017
  172. P. RutkowskiE.M. SłominskaM. SzołkiewiczE. AleksandrowiczR.T. SmolenskiW. WołyniecM. RenkeK. WisterowiczJ. SwierczynskiB. RutkowskiRelationship between uremic toxins and oxidative stress in patients with chronic renal failureScand. J. Urol. Nephrol.20074124324810.1080/0036559060101717017469035
  173. Y. IkedaT. SuehiroT. ItaharaY. InuiH. ChikazawaM. InoueK. AriiK. HashimotoHuman serum paraoxonase concentration predicts cardiovascular mortality in hemodialysis patientsClin. Nephrol.20076735836510.5414/CNP6735817598371
  174. M.F. WeissP. ErhardF.A. Kader-AttiaY.C. WuMechanisms for the formation of glycoxidation products in end-stage renal diseaseKidney Int.2000572571258510.1046/j.1523-1755.2000.00117.x10844627
  175. T. MiyataK. KurokawaAdvanced glycation and lipoxidation end products role of reactive carbonyl compounds generated during carbohydrate and lipid metabolismJ. Am. Soc. Nephrol.2000111744175210966500
  176. E.R. StadtmanR.L. LevineFree radical-mediated oxidation of free amino acids and amino acid residues in proteinsAmino Acids20032520721810.1007/s00726-003-0011-214661084
  177. G. BastaA.M. SchmidtR. De CaterinaAdvanced glycation end products and vascular inflammation: Implications for accelerated atherosclerosis in diabetesCardiovasc. Res.20046358259210.1016/j.cardiores.2004.05.00115306213
  178. R. BucalaR. MitchellK. ArnoldT. InnerarityH. VlassaraA. CeramiIdentification of the major site of Apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptorJ. Biol. Chem.199527010828108327738020
  179. R.L. KleinM. LaiminsM.F. Lopes-VirellaIsolation, characterization, and metabolism of the glycated and nonglycated subfractions of low-density lipoproteins isolated from Type I diabetic patients and nondiabetic subjectsDiabetes1995441093109810.2337/diab.44.9.10937657034
  180. A. Negre SalvayreC. CoatrieuxC. IngueneauR. SalvayreAdvanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitorsBr. J. Pharmacol.200815362010.1038/sj.bjp.070739517643134
  181. M. KalousovaT. ZimaV. TesařS. ŠtípekS. SulkováAdvanced glycation end products in clinical nephrologyKidney Blood Press. Res.200427182810.1159/00007553314679311
  182. M. KalousovaT. ZimaV. TesařJ. LachmanováAdvanced glycation end products and advanced oxidation protein products in hemodialyzed patientsBlood Purif.20032053153610.1159/000066956
  183. R. SchinzelG. MünchA. HeidlandK. SebekovaAdvanced glycation end products in end-stage renal disease and their removalNephron20018729530310.1159/00004593411287772
  184. B. CanaudJ.P. CristolM. MorenaH. Leray-MoraguesJ.Y. BoscF. VaussenatImbalance of oxidants and antioxidants in haemodialysis patientsBlood Purif.1999179910610.1159/00001438110449867
  185. F. LocatelliB. CanaudK.U. EckardtP. StenvinkelC. WannerC. ZoccaliOxidative stress in end-stage renal disease: An emerging threat to patient outcomeNephrol. Dial. Transplant.2003181272128010.1093/ndt/gfg07412808161
  186. F.H. VerbruggeW. TangS.L. HazenProtein carbamylation and cardiovascular diseaseKidney Int.20158847447810.1038/ki.2015.16626061545
  187. R.A. KoethK. Kalantar-ZadehZ. WangX. FuW.H.W. TangS.L. HazenProtein carbamylation predicts mortality in ESRDJ. Am. Soc. Nephrol.20132485386110.1681/ASN.201203025423431074
  188. A.H. BergC. DrechslerJ. WengerR. BuccafuscaT. HodS. KalimW. RammaS.M. ParikhH. SteenD.J. FriedmanCarbamylation of serum albumin as a risk factor for mortality in patients with kidney failureSci. Transl. Med.2013510.1126/scitranslmed.300521823467560
  189. J.L. MehtaA.G. BasnakianInteraction of carbamylated LDL with LOX-1 in the induction of endothelial dysfunction and atherosclerosisEur. Heart J.2014352996299710.1093/eurheartj/ehu12224694664
  190. S.J. NichollsMyeloperoxidase and cardiovascular diseaseArterioscler. Thromb. Vasc. Biol.2005251102111110.1161/01.ATV.0000163262.83456.6d15790935
  191. A. RutgersP. HeeringaJ.P. KoomanF.M. van der SandeJ.W. Cohen TravaertPeripheral blood myeloperoxidase activity increases during hemodialysisKidney Int.20036476076210.1046/j.1523-1755.2003.00139.x12846778
  192. P. StenvinkelStatin treatment and diabetes affect myeloperoxidase activity in maintenance hemodialysis patientsClin. J. Am. Soc. Nephrol.2006128128710.2215/CJN.0128100517699218
  193. S. WadaK. SugiokaT. NarukoY. KatoT. ShibataT. InoueM. InabaM. OhsawaM. YoshiyamaM. UedaMyeloperoxidase and progression of aortic valve stenosis in patients undergoing hemodialysisJ. Heart Valve Dis.20132264064724383374
  194. R.C. MurphyK.M. JohnsonCholesterol, reactive oxygen species, and the formation of biologically active mediatorsJ. Biol. Chem.2008283155211552510.1074/jbc.R70004920018285330
  195. A.J. BrownW. JessupOxysterols and atherosclerosisAtherosclerosis199914212810.1016/S0021-9150(98)00196-89920502
  196. H.N. HodisD.W. CrawfordA. SevanianCholesterol feeding increases plasma and aortic tissue cholesterol oxide levels in parallel: Further evidence for the role of cholesterol oxidation in atherosclerosisAtherosclerosis19918911712610.1016/0021-9150(91)90051-41793439
  197. S. Garcia-CrusetK.L. CarpenterF. GuardiolaB.K. SteinM.J. MitchinsonOxysterol profiles of normal human arteries, fatty streaks and advanced lesionsFree Radic. Res.200135314110.1080/1071576010030057111697115
  198. G. LizardS. MonierC. CordeletL. GesquièreV. DeckertS. GueldryL. LagrostP. GambertCharacterization and comparison of the mode of cell death, apoptosis versus necrosis, induced by 7β-hydroxycholesterol and 7-ketocholesterol in the cells of the vascular wallArterioscler. Thromb. Vasc. Biol.1999191190120010.1161/01.ATV.19.5.119010323769
  199. N. ShibataC.K. GlassMacrophages, oxysterols and atherosclerosisCirculation2010742045205110.1253/circj.CJ-10-0860
  200. E. NishioY. WatanabeOxysterols induced apoptosis in cultured smooth muscle cells through CPP32 protease activation and bcl-2 protein downregulationBiochem. Biophys. Res. Commun.199622692893410.1006/bbrc.1996.14528831713
  201. S. LemaireG. LizardS. MonierC. MiguetS. GueldryF. VolotP. GambertD. NéelDifferent patterns of IL-1beta secretion, adhesion molecule expression and apoptosis induction in human endothelial cells treated with 7α-, 7β-hydroxycholesterol, or 7-ketocholesterolFEBS Lett.199844043443910.1016/S0014-5793(98)01496-39872417
  202. Y.C. O’CallaghanJ.A. WoodsN.M. O’BrienOxysterol-induced cell death in U937 and HepG2 cells at reduced and normal serum concentrationsEur. J. Nutr.19993825526210.1007/s00394005007510784381
  203. G. LizardV. DeckertL. DubrezM. MoisantP. GambertL. LagrostInduction of apoptosis in endothelial cells treated with cholesterol oxidesAm. J. Pathol.1996148162516388623930
  204. F.R. MaxfieldI. TabasRole of cholesterol and lipid organization in diseaseNature200543861262110.1038/nature0439916319881
  205. C. PrunetT. MontangeA. VéjuxA. LaubrietJ.F. RohmerJ.M. RiedingerA. AthiasS. Lemaire EwingD. NéelJ.M. PetitMultiplexed flow cytometric analyses of pro- and anti-inflammatory cytokines in the culture media of oxysterol-treated human monocytic cells and in the sera of atherosclerotic patientsCytom. Part A200669A35937310.1002/cyto.a.2027216604541
  206. S. Lemaire-EwingC. PrunetT. MontangeA. VejuxA. BerthierG. BessèdeL. CorcosP. GambertD. NéelG. LizardComparison of the cytotoxic, pro-oxidant and pro-inflammatory characteristics of different oxysterolsCell. Biol. Toxicol.2005219711410.1007/s10565-005-0141-216142584
  207. M. RosenblatM. AviramOxysterol-induced activation of macrophage NADPH-oxidase enhances cell-mediated oxidation of LDL in the atherosclerotic apolipoprotein E deficient mouse: Inhibitory role for vitamin EAtherosclerosis2002160698010.1016/S0021-9150(01)00563-911755924
  208. M.L. SelleyJ.A. McGuinessN.G. ArdlieThe effect of cholesterol oxidation products on human platelet aggregationThromb. Res.19968344946110.1016/0049-3848(96)00154-58885139
  209. V.M. OlkkonenM. LehtoOxysterols and oxysterol binding proteins: Role in lipid metabolism and atherosclerosisAnn. Med.20093656257210.1080/07853890410018907
  210. L. IulianoF. MichelettaS. NatoliS. Ginanni CorradiniM. IappelliW. EliseiL. GiovannelliF. VioliU. DiczfalusyMeasurement of oxysterols and alpha-tocopherol in plasma and tissue samples as indices of oxidant stress statusAnal. Biochem.200331221722310.1016/S0003-2697(02)00467-012531208
  211. V.N. BochkovO.V. OskolkovaK.G. BirukovA.-L. LevonenC.J. BinderJ. StöcklGeneration and biological activities of oxidized phospholipidsAntioxid. Redox Signal.2010121009105910.1089/ars.2009.259719686040
  212. R. RadiJ.S. BeckmanK.M. BushB.A. FreemanPeroxynitrite-induced membrane lipid peroxidation: The cytotoxic potential of superoxide and nitric oxideArch. Biochem. Biophys.199128848148710.1016/0003-9861(91)90224-71654835
  213. A. JerlichA.R. PittR.J. SchaurC.M. SpickettPathways of phospholipid oxidation by HOCl in human LDL detected by LC-MSFree Radic. Biol. Med.20002867368210.1016/S0891-5849(99)00273-710754262
  214. A.C. CarrC.C. WinterbournJ.J. van den BergPeroxidase-mediated bromination of unsaturated fatty acids to form bromohydrinsArch. Biochem. Biophys.199632722723310.1006/abbi.1996.01148619607
  215. H. KuhnJ. BelknerR. WiesnerA.R. BrashOxygenation of biological membranes by the pure reticulocyte lipoxygenaseJ. Biol. Chem.199026518351183612120232
  216. J. BelknerR. WiesnerJ. RathmanJ. BarnettE. SigalH. KuhnOxygenation of lipoproteins by mammalian lipoxygenasesEur. J. Biochem.199321325126110.1111/j.1432-1033.1993.tb17755.x8477699
  217. D. HeydeckJ.M. UpstonH. ViitaS. Ylä-HerttualaR. StockerOxidation of LDL by rabbit and human 15-lipoxygenase: Prevalence of nonenzymatic reactionsJ. Lipid Res.2001421082108811441135
  218. J.A. BerlinerN. LeitingerS. TsimikasThe role of oxidized phospholipids in atherosclerosisJ. Lipid Res.20095020721210.1194/jlr.R800074-JLR20019059906
  219. A.L. ColeG. SubbanagounderS. MukhopadhyayJ.A. BerlinerD.K. VoraOxidized phospholipid-induced endothelial cell/monocyte interaction is mediated by a cAMP-dependent R-Ras/PI3-kinase pathwayArterioscler. Thromb. Vasc. Biol.2003231384139010.1161/01.ATV.0000081215.45714.7112805072
  220. R. LiK.P. MouillesseauxD. MontoyaD. CruzN. GharaviM. DunL. KoroniakJ.A. BerlinerIdentification of prostaglandin E2 receptor subtype 2 as a receptor activated by OxPAPCCirc. Res.20069864265010.1161/01.RES.0000207394.39249.fc16456101
  221. D.K. VoraZ.T. FangS.M. LivaT.R. TynerF. ParhamiA.D. WatsonT.A. DrakeM.C. TerritoJ.A. BerlinerInduction of P-selectin by oxidized lipoproteins. Separate effects on synthesis and surface expressionCirc. Res.19978081081810.1161/01.RES.80.6.8109168783
  222. G.J. DeverR. BensonC.L. WainwrightS. KennedyC.M. SpickettPhospholipid chlorohydrin induces leukocyte adhesion to ApoE−/− mouse arteries via upregulation of P-selectinFree Radic. Biol. Med.20084445246310.1016/j.freeradbiomed.2007.10.03818005671
  223. M. RouhanizadehJ. HwangR.E. ClempusL. MarcuB. LassègueA. SevanianT.K. HsiaiOxidized-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine induces vascular endothelial superoxide production: Implication of NADPH oxidaseFree Radic. Biol. Med.2005391512152210.1016/j.freeradbiomed.2005.07.01316274886
  224. E.A. WeinsteinH. LiJ.A. LawsonJ. RokachG.A. FitzGeraldP.H. AxelsenProthrombinase acceleration by oxidatively damaged phospholipidsJ. Biol. Chem.2000275229252293010.1074/jbc.M00243820010801844
  225. O. SafaK. HensleyM.D. SmirnovC.T. EsmonN.L. EsmonLipid oxidation enhances the function of activated protein CJ. Biol. Chem.20012761829183610.1074/jbc.M00593120011054414
  226. V.N. BochkovD. MechtcheriakovaM. LucernaJ. HuberR. MalliW.F. GraierE. HoferB.R. BinderN. LeitingerOxidized phospholipids stimulate tissue factor expression in human endothelial cells via activation of ERK/EGR-1 and Ca++/NFATBlood20029919920610.1182/blood.V99.1.19911756172
  227. N. HaserückW. ErlD. PandeyG. TigyiP. OhlmannC. RavanatC. GachetW. SiessThe plaque lipid lysophosphatidic acid stimulates platelet activation and platelet-monocyte aggregate formation in whole blood: Involvement of P2Y1 and P2Y12 receptorsBlood20041032585259210.1182/blood-2003-04-112714645014
  228. G.K. MaratheG.A. ZimmermanS.M. PrescottT.M. McIntyreActivation of vascular cells by PAF-like lipids in oxidized LDLVascul. Pharmacol.20023819320010.1016/S1537-1891(02)00169-612449015
  229. G. SubbanagounderN. LeitingerP.T. ShihK.F. FaullJ.A. BerlinerEvidence that phospholipid oxidation products and/or platelet-activating factor play an important role in early atherogenesis: In vitro and In vivo inhibition by WEB 2086Circ. Res.19998531131810.1161/01.RES.85.4.31110455059
  230. A. TokumuraT. SumidaM. ToujimaK. KogureK. FukuzawaPlatelet-activating factor (PAF)-like oxidized phospholipids: Relevance to atherosclerosisBiofactors200013293310.1002/biof.552013010611237195
  231. H.-P. DeignerA. HermetterOxidized phospholipids: Emerging lipid mediators in pathophysiologyCurr. Opin. Lipidol.20081928929410.1097/MOL.0b013e3282fe1d0e18460921
  232. E.A. PodrezIdentification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36J. Biol. Chem.2002277385033851610.1074/jbc.M20331820012105195
  233. S.L. HazenOxidized phospholipids as endogenous pattern recognition ligands in innate immunityJ. Biol. Chem.2008283155271553110.1074/jbc.R70005420018285328
  234. J. FrostegårdE. SvenungssonR. WuI. GunnarssonI.E. LundbergL. KlareskogS. HörkköJ.L. WitztumLipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestationsArthritis Rheum.20055219220010.1002/art.2078015641060
  235. L.J. MarnettLipid peroxidation—DNA damage by malondialdehydeMutat. Res.1999424839510.1016/S0027-5107(99)00010-X10064852
  236. L.A. VanderVeenM.F. HashimY. ShyrL.J. MarnettInduction of frameshift and base pair substitution mutations by the major DNA adduct of the endogenous carcinogen malondialdehydePNAS2003100142471425210.1073/pnas.233217610014603032
  237. K. UchidaRole of reactive aldehyde in cardiovascular diseasesFree Radic. Biol. Med.2000281685169610.1016/S0891-5849(00)00226-410946210
  238. W. PalinskiV.A. OrdA.S. PlumpJ.L. BreslowD. SteinbergJ.L. WitztumApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serumArterioscler. Thromb. Vasc. Biol.19941460561610.1161/01.ATV.14.4.605
  239. D. Del RioA.J. StewartN. PellegriniA review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stressNutr. Metabol. Cardiovasc. Dis.20051531632810.1016/j.numecd.2005.05.00316054557
  240. A.F. De VecchiF. BamontiC. NovembrinoS. IppolitoL. GuerraS. LonatiS. SaliniC.S. AmanE. Scurati-ManzoniG. CighettiFree and total plasma malondialdehyde in chronic renal insufficiency and in dialysis patientsNephrol. Dial. Transplant.2009242524252910.1093/ndt/gfp10219264746
  241. M.I. YilmazM. SaglamK. CaglarE. CakirA. SonmezT. OzgurtasA. AydinT. EyiletenO. OzcanC. AcikelThe determinants of endothelial dysfunction in CKD: Oxidative stress and asymmetric dimethylarginineAm. J. Kidney Dis.200647425010.1053/j.ajkd.2005.09.02916377384
  242. C. CapusaI. StoianE. RusD. LixandruC. BarbulescuG. MircescuDoes dialysis modality influence the oxidative stress of uremic patients?Kidney Blood Press. Res.20123522022510.1159/00033156022223182
  243. G. CaimiC. CarolloM. MontanaR. IatrinoB. BondìR. Lo PrestiNitric oxide metabolites, leukocyte activation markers and oxidative status in dialyzed subjectsBlood Purif.20092719419810.1159/00019321819153478
  244. M. DiricanE. SarandolZ. SerdarN. OcakK. DilekOxidative status and prevalent cardiovascular disease in patients with chronic renal failure treated by hemodialysisClin. Nephrol.20076814415010.5414/CNP6814417915616
  245. J. BoberK. KedzierskaE. KwiatkowskaE. StachowskaE. GołembiewskaO. MazurZ. StaniewiczK. CiechanowskiD. ChlubekDoes oxidative stress affect the activity of the sodium-proton exchanger?Ann. Acad. Med. Stetin.20105651222053621
  246. H. EsterbauerR.J. SchaurH. ZollnerChemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydesFree Radic. Biol. Med.1991118112810.1016/0891-5849(91)90192-61937131
  247. D.R. PetersenJ.A. DoornReactions of 4-hydroxynonenal with proteins and cellular targetsFree Radic. Biol. Med.20043793794510.1016/j.freeradbiomed.2004.06.01215336309
  248. W.G. SiemsS.J. HapnerF.J. Van Kuijk4-Hydroxynonenal inhibits Na(+)-K(+)-ATPaseFree Radic. Biol. Med.19962021522310.1016/0891-5849(95)02041-18746442
  249. B.S. KristalB.K. ParkB.P. Yu4-Hydroxyhexenal is a potent inducer of the mitochondrial permeability transitionJ. Biol. Chem.1996271603360388626387
  250. J.J. ChenB.P. YuAlterations in mitochondrial membrane fluidity by lipid peroxidation productsFree Radic. Biol. Med.19941741141810.1016/0891-5849(94)90167-87835747
  251. K. UchidaK. ItakuraS. KawakishiH. HiaiS. ToyokuniE.R. StadtmanCharacterization of Epitopes Recognized by 4-Hydroxy-2-nonenal Specific AntibodiesArch. Biochem. Biophys.199532424124810.1006/abbi.1995.00368554315
  252. H.F. HoffJ. O’NeilG.M. ChisolmT.B. ColeO. QuehenbergerH. EsterbauerG. JürgensModification of low density lipoprotein with 4-hydroxynonenal induces uptake by macrophagesArterioscler. Thromb. Vasc. Biol.1989953854910.1161/01.ATV.9.4.538
  253. J. RuefG.N. RaoF. LiC. BodeC. PattersonA. BhatnagarM.S. RungeInduction of Rat Aortic Smooth Muscle Cell Growth by the Lipid Peroxidation Product 4-Hydroxy-2-NonenalCirculation1998971071107810.1161/01.CIR.97.11.10719531254
  254. U. HerbstM. ToborekS. KaiserM.P. MattsonB. Hennig4-Hydroxynonenal induces dysfunction and apoptosis of cultured endothelial cellsJ. Cell. Physiol.199918129530310.1002/(SICI)1097-4652(199911)181:2<295::AID-JCP11>3.0.CO;2-I10497308
  255. Y.-M. GoP.J. HalveyJ.M. HansenM. ReedJ. PohlD.P. JonesReactive aldehyde modification of thioredoxin-1 activates early steps of inflammation and cell adhesionAm. J. Pathol.20071711670168110.2353/ajpath.2007.07021817982132
  256. M. PiroddiD. BartoliniS. CiffolilliF. GalliNondialyzable uremic toxinsBlood Purif.201335304110.1159/00035084623676834
  257. O. SommerburgT. GruneH. HamplE. RiedelF.J. van KuijkJ.H. EhrichW.G. SiemsDoes long-term treatment of renal anaemia with recombinant erythropoietin influence oxidative stress in haemodialysed patients?Nephrol. Dial. Transplant.1998132583258710.1093/ndt/13.10.25839794564
  258. M.S.S. AlhamdaniA.H.A.M. Al-KassirN.A. JaleelA.M. HmoodH.M. AliElevated levels of Alkanals, alkenals and 4-ho-alkenals in plasma of hemodialysis patientsAm. J. Nephrol.20062629930310.1159/00009430516804293
  259. E.H. BaeS. ChoS.Y. JooS.K. MaS.H. KimJ. LeeS.W. Kim4-Hydroxy-2-hexenal-induced apoptosis in human renal proximal tubular epithelial cellsNephrol. Dial. Transplant.2011263866387310.1093/ndt/gfr38621771752
  260. J.D. MorrowK.E. HillR.F. BurkT.M. NammourK.F. BadrL.J. Roberts 2ndA series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanismProc. Natl. Acad. Sci. USA1990879383938710.1073/pnas.87.23.93832123555
  261. L.J. Roberts IIJ.D. MorrowMeasurement of F2-isoprostanes as an index of oxidative stress in vivoFree Radic. Biol. Med.20002850551310.1016/S0891-5849(99)00264-610719231
  262. L.J. Roberts IIJ.P. FesselThe biochemistry of the isoprostane, neuroprostane, and isofuran pathways of lipid peroxidationChem. Phys. Lipids200412817318610.1016/j.chemphyslip.2003.09.01615037162
  263. J.D. MorrowT.A. MintonL.J. RobertsThe F2-isoprostane, 8-epi-prostaglandin F2α, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonistProstaglandins19924415516310.1016/0090-6980(92)90077-71438879
  264. T. YuraM. FukunagaR. KhanG.N. NassarK.F. BadrFree-radical-generated F2-isoprostane stimulates cell proliferation and endothelin-1 expression on endothelial cellsKidney Int.19995647147810.1046/j.1523-1755.1999.00596.x10432385
  265. M. FukunagaN. MakitaL.J. RobertsJ.D. MorrowK. TakahashiK.F. BadrEvidence for the existence of F2-isoprostane receptors on rat vascular smooth muscle cellsAm. J. Physiol.199326416191624
  266. K. TakahashiT.M. NammourM. FukunagaJ. EbertJ.D. MorrowL.J. Roberts 2ndR.L. HooverK.F. BadrGlomerular actions of a free radical-generated novel prostaglandin, 8-epi-prostaglandin F2 alpha, in the rat. Evidence for interaction with thromboxane A2 receptorsJ. Clin. Investig.19929013614110.1172/JCI1158261386085
  267. J.F. ReckelhoffV. KanjiL.C. RacusenA.M. SchmidtS.D. YanJ. MorrowL.J. RobertsA.K. SalahudeenVitamin E ameliorates enhanced renal lipid peroxidation and accumulation of F2-isoprostanes in aging kidneysAm. J. Physiol.1998274767774
  268. S. CottoneM.C. LoritoR. RiccobeneE. NardiOxidative stress, inflammation and cardiovascular disease in chronic renal failureJ. Nephrol.20082117517918446711
  269. C.-Y.J. LeeS.H. HuangA.M. JennerB. HalliwellMeasurement of F2-isoprostanes, hydroxyeicosatetraenoic products, and oxysterols from a single plasma sampleFree Radic. Biol. Med.2008441314132210.1016/j.freeradbiomed.2007.12.02618226605
  270. M. RamezaniF. NazemianJ. ShamsaraR. KoohrokhiA.H. MohammadpourEffect of Ω-3 fatty acids on plasma level of 8-isoprostane in kidney transplant patientsJ. Ren. Nutr.20112119619910.1053/j.jrn.2010.06.02321093286
  271. E.M. SimmonsA. LangoneM.T. SezerJ.P. VellaP. RecuperoJ.D. MorrowT.A. IkizlerJ. HimmelfarbEffect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patientsTransplantation20057991491910.1097/01.TP.0000157773.96534.2915849543
The underlying source XML for this text is taken from The license for the article is Creative Commons Attribution. The main subject has been identified as chronic kidney disease.